

Chiral Pyridin-3-ones and Pyridines: Syntheses of Enantiopure 2,4-Disubstituted 6-Hydroxy-1,6-Dihydro-2*H*-Pyridin-3-ones, 2,3-Disubstituted 4-Iodopyridines, and Enantiopure 2,3-Disubstituted 4-Pyridinemethanols


Irfan Husain,[†] Mohammad Saquib,[†] Vikas Bajpai,[‡] Brijesh Kumar,[‡] and Arun K. Shaw^{†,*}

[†]Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, PO Box 173, Lucknow-226001, India

[‡]Sophisticated Analytical Instruments Facility, CSIR-Central Drug Research Institute, PO Box 173, Lucknow-226001, India

Supporting Information

ABSTRACT: The development of an innovative method to access enantiopure 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones starting from *D*-glucal via the aza-Achmatowicz transformation has been described. These highly functionalized pyridin-3-ones have been utilized for the synthesis of contiguously substituted pyridines through a rapid and efficient Et₃N/Ac₂O promoted cycl-elimination, aromatization cascade, allowing the facile assembly of important pyridine-based building blocks like 2-substituted 3-acetoxy-4-iodopyridines and enantiopure 2-substituted 3-acetoxy-4-pyridinemethanols possessing benzylic stereogenic centers, whose synthesis otherwise would be tedious. The utilization of commercially available sugars as starting materials, mild reaction conditions, catalytic transfer hydrogen (CTH) of α -furfuryl azide derivatives, transfer of chiral aryl/alkyl methanols from enulosides to pyridin-3-ones and pyridines, high yields, and short reaction times are key features of this method. The utility of the method has been further exemplified by demonstrating the usage of the 2-substituted 3-acetoxy-4-iodopyridine for the construction of biologically significant molecules like 2,7-disubstituted furo[2,3-*c*]pyridines and 7,7'-disubstituted 2,2'-bifuro[2,3-*c*]pyridines.



INTRODUCTION

Functionalized pyridines are biologically and synthetically important molecules. Their wide distribution in an array of important compounds ranging from natural products and pharmaceuticals^{1–8} to catalysts^{9–14} and polymers^{15–17} is ample testimony of their significance. Among pyridines, chiral pyridines form a special subcategory (Figure 1). Not only are they present as structural elements in a plethora of important molecules like natural products,^{4,5} but they also serve as chiral ligands^{11,12} and important building blocks in organic synthesis.¹⁸

Though a large number of methods for synthesis of substituted pyridines are known, relatively fewer reports on preparation of substituted chiral pyridines are documented. Consequently construction of chiral pyridines with diverse substitution patterns remains a much sought after goal.^{12,19–25} Likewise substituted 4-iodopyridines^{26–29} are another important class of pyridine molecules widely employed as versatile building blocks for the synthesis of different types of molecules exhibiting potent biological activities^{26,27} and natural products.^{28,29} The increasing use of cross-coupling methodologies, Suzuki–Miyaura, Buchwald–Hartwig, Sonogashira reactions, etc., in organic synthesis have further widened the utility of these building blocks.^{26–37} Regioselective synthesis of 4-

iodopyridines is usually achieved by ortholithiation^{26–28} or Sandmeyer reaction³⁸ by adopting reaction conditions that are not compatible with sensitive functional groups that may be present on the pyridine ring.³⁷ Therefore, the search for a milder and more efficient method for the construction of substituted 4-iodopyridines remains an active research field for the chemical community.³⁷

Aza-Achmatowicz transformation is a versatile synthetic strategy widely employed for the synthesis of biologically important chiral compounds and natural products.^{39–45} The transformation of *D*-glucal-derived 2-furfurylamines into 2-substituted 1,6-dihydro-6-hydroxy-2*H*-pyridin-3-ones involving aza-Achmatowicz chemistry^{43,45} becomes all the more relevant in the context of the increasing stress on the synthesis of organic molecules from renewable feedstock such as carbohydrate rather than steadily diminishing petroleum resources.^{46,47}

However utility of this route is greatly restricted by its inability to provide access to 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones having substitution other than at position 2 of the pyridone ring.⁴⁴ Thus development of a new synthetic strategy that allows for the construction of highly functionalized

Received: August 9, 2011

Published: September 28, 2011




Figure 1. Structure of some chiral pyridine-based natural and synthetic compounds containing benzylic stereogenic centers.

6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones using the aza-Achmatowicz chemistry would significantly expand the utility of this approach.⁴⁸

In the backdrop of the above discussion, we now report the development of a new method that allows for the construction of 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones from *D*-glucal, using the aza-Achmatowicz chemistry. This new method takes advantage of our earlier report on synthesis of enantiopure 2,3-disubstituted furans from *D*-glucal⁴⁹ to access novel 2,3-disubstituted furylamines, which on subjection to aza-Achmatowicz reaction furnished the desired 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones in good yields. These valuable pyridin-3-one moieties could serve as useful building blocks for the synthesis of highly functionalized enantiopure piperidines and pyridines based synthetic and natural products.⁴⁸

To demonstrate the usefulness of these 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-one building blocks, we have developed a novel, mild, and facile $\text{Et}_3\text{N}/\text{Ac}_2\text{O}$ promoted conversion of these pyridine-3-ones into the corresponding 2,3,4-trisubstituted pyridines thus allowing easy access to important trisubstituted pyridine molecules, like 4-iodopyridines, and enantiopure 4-pyridinemethanols possessing benzylic stereogenic centers^{4,50–54} whose synthesis otherwise would be tedious.^{27,37,52} The utility of the 3-acetoxy-4-iodopyridines obtained by the method described herein has also been demonstrated by their facile transformation to biologically important molecules like furopyridines^{31–34} and bifuropyridines.^{35,36}

RESULTS AND DISCUSSION

To achieve the synthesis of the target 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones, we believed that if suitable reaction conditions could be optimized to access simple 2-substituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones from unbranched 2,3-dideoxy-hex-2-enopyranosides, the same reaction conditions could be translated to obtain the desired 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones from C-3 branched 2,3-dideoxy-hex-2-enopyranosides (Figure 2).

We initiated our work with isoamyl-6-*O*-trimethylacetyl-2,3-dideoxy-hex-2-enopyranosid-4-ulose (**1**), which was converted into furan **3** by adopting our previously reported method.⁴⁹ A modified Mitsunobu reaction was employed to transform **3** into α -furfurylazide **4** in 74% yield in the presence of DPPA/DBU in dry toluene^{45,55} followed by its hydrogenation over Pd–C/





Figure 2. General synthetic approach for the synthesis of functionalized pyridin-3-ones and pyridines and their application.


H_2 to 2-furfurylamine, which was isolated as its tosyl-protected derivative **5** in 78% yield. It was then subjected to aza-Achmatowicz rearrangement in the presence of NBS/ $\text{NaOAc}\cdot 3\text{H}_2\text{O}$ in THF/ H_2O (4:1) to obtain 1,6-dihydro-2*H*-pyridin-3-one **6** in 83% yield (Scheme 1).⁵⁶

Once the strategy for the conversion of hex-2-enopyranosid-4-ulose **1** into 1,6-dihydro-2*H*-pyridin-3-one **6** had been worked out, we directed our attention to utilize this strategy for the construction of 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones **12** from stereochemically pure C-3 branched 2,3-dideoxy-hex-2-enopyranosid-4-uloses **7**, synthesized by using our earlier reported method.⁵⁷

To achieve the synthesis of **12** successfully from **7** by adopting the above-described strategy to obtain **6** from the enuloside **1** via the key intermediate furan **5**, the protection of the secondary hydroxyl group at C-1' of the hex-2-enopyranosid-4-uloses **7a–c** was necessary. First, the acetylation of C-1' benzylic hydroxy group in **7a** was attempted, which however resulted in the formation of a mixture of diastereomers. To overcome this difficulty, we carried out TBS protection of the benzylic hydroxy group at C-1' by using TBSOTf/2,6-lutidine in dry DCM, which furnished the TBS-protected derivative **8a** as a single isomer in 83% yield.⁵⁸ The TBS-protected derivative **8a** was transformed into the

Scheme 1^a

corresponding 2-furyl glycol **9a**⁴⁹ in 74% yield followed by its azidation with DPPA/DBU to obtain the enantiopure 2,3-disubstituted furylazide **10a** (Scheme 2). It was now subjected


Scheme 2^a

to hydrogenation over Pd–C to access the corresponding 2,3-disubstituted furylamine, which was isolated as its tosyl-protected derivative **11a** in 60% yield. Moreover, its yield was improved to 70% when Et₃SiH/Pd–C mediated catalytic transfer hydrogenation (CTH) of **10a** was performed by adopting the protocol developed by McMurray and Mandal.⁵⁹ The resulting 2,3-disubstituted tosyl-protected furylamine **11a** was then subjected to undergo aza-Achmatowicz reaction in the presence of NBS/NaOAc·3H₂O in THF/H₂O (4:1) at –5 °C → 0 °C to obtain the desired 4-substituted 1,6-dihydro-2H-pyridin-3-one **12a**. To our surprise, the reaction did not proceed here even after stirring the reaction mixture for 5 h. Therefore, the temperature of the reaction mixture was raised to room temperature, but under this condition, the reaction proceeded very slowly. However, when the same reaction was carried out in presence of NBS alone at –5 °C → RT, the reaction progressed smoothly to completion in about 4 h to furnish 4-substituted 1,6-dihydro-2H-pyridin-3-one **12a** in 66% yield.⁶⁰ That the transformation of crowded 2,3-disubstituted furan **11a** to the pyridin-3-one **12a** in the presence of NBS/NaOAc·3H₂O was unsuccessful could be attributed to the weaker reactivity of *in situ* generated brominating agent acetyl hypobromite (CH₃COOBr) from NBS and the buffer anion compared with that of NBS alone successfully utilized for the same transformation.⁶¹

The above optimized synthetic strategy was now successfully exploited to transform a series of C-3 branched 2,3-dideoxyhex-2-enopyranosid-4-ulose **7b**, **7c**, and **7d**⁶² into the corresponding 2,4-disubstituted 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones **12b–d** (Scheme 2). While compounds **12b** and **12d** were easily purified by column chromatography (SiO₂), the column purification of the pyridin-3-one **12c** led to its degradation, and that is why it was used as such without further purification for its next reaction.


Our next effort was to develop a synthetic route to 4-iodopyridones from enuloside **1**. Our attempt to synthesize 4-iodo-6-hydroxy-1,6-dihydro-2H-pyridin-3-one **16** from **1** using this strategy was futile because in this case the CTH of 3-iodo- α -furfurylazide **15** in the presence of Et₃SiH/Pd–C led to the reductive deiodination⁶³ instead of reduction of the azide group (Scheme 3).

Our next effort was to develop a synthetic route to 4-iodopyridones from enuloside **1**. Our attempt to synthesize 4-iodo-6-hydroxy-1,6-dihydro-2H-pyridin-3-one **16** from **1** using this strategy was futile because in this case the CTH of 3-iodo- α -furfurylazide **15** in the presence of Et₃SiH/Pd–C led to the reductive deiodination⁶³ instead of reduction of the azide group (Scheme 3).

Scheme 3^a

We, therefore, devised a different synthetic approach to achieve the synthesis of 2-substituted 4-iodo-6-hydroxy-1,6-dihydro-2H-pyridin-3-one **16**. Thus, when 2-substituted 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones **6** and **17**⁴⁵ were treated with I₂/pyridine in CCl₄, the corresponding 2-substituted 4-iodo-6-hydroxy-1,6-dihydro-2H-pyridin-3-ones **16** and **18** were obtained in good yields (Scheme 4).⁶⁴


Once the route for the synthesis of enantiopure 2- and 2,4-difunctionalized 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones had

Scheme 4^a

^aReagents and conditions: (a) I₂, CCl₄, pyridine, -5 °C → 0 °C, 2 h; (b) I₂, CCl₄, pyridine, -5 °C → 0 °C, 2 h, 81%.

been successfully established, we turned our attention to transform these pyridone-3-ones into the azasugars.^{42,44} To achieve this goal successfully, the protection of the C-6 hydroxy group was essential prior to Luche's reduction of the C-3 carbonyl group. Thus, 6-hydroxy-1,6-dihydro-2H-pyridin-3-one **6** was treated with Ac₂O/pyridine to obtain its 6-acetoxy derivative. The reaction proceeded smoothly with the formation of a single spot on TLC. However, to our surprise spectral analysis of the column purified product, which was isolated in 78% yield, revealed it to be a 2-trimethylacetoxymethyl-3-acetoxy-pyridine **19** instead of the expected acetyl derivative of **6** (Table 1). A literature survey revealed two

Table 1. Optimization of Reaction Conditions for the Transformation of Pyridin-3-ones into Pyridines



entry	reagents	temp (°C)	time (min)	yield % (pyridine)
1	pyridine/Ac ₂ O	0 to RT	30	78 (19)
2	DBU/DMF	0 to RT	30	starting material degrades
3	pyridine	0 to RT	30	no reaction
4	Et ₃ N	0 to RT	30	no reaction
5	Et ₃ N/Ac ₂ O	0 to RT	30	76 (19)
6	pyridine/Ac ₂ O	0	90	66 (19)
7	Et ₃ N/Ac ₂ O	0	30	91 (19)
8	Et ₃ N/Ac ₂ O	0	30	94 (20)

reports on transformation of 1,6-dihydro-2H-pyridin-3-one into 3-hydroxy pyridines. But both these reports are concerned with the conversion of simple 1,6-dihydro-2H-pyridin-3-one obtained by RCM of open chain precursors rather than that of 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones obtained by aza-Achmatowicz reaction as in our case.^{65,66}

Since substituted pyridines are an important class of compounds possessing various biological properties, at this stage we turned our attention to optimizing the reaction conditions to obtain substituted pyridines from their respective 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones. Thus, a series of experiments was conducted to make this transformation more effective in terms of yield and reaction time. First, we tried a method developed by K. Yoshida et al. to transform 2-

substituted 6-hydroxy-1,6-dihydro-2H-pyridin-3-one **6** into its corresponding 2,3-disubstituted pyridine in the presence of DBU/DMF at 0 °C to RT (Table 1, entry 1).⁶⁵ Here the starting material was completely degraded within 30 min. Changing the base from DBU to pyridine or Et₃N also did not make this transformation possible. In our next attempt, Et₃N was used along with Ac₂O at 0 °C → RT (Table 1, entry 5). In this case, the reaction proceeded smoothly to completion in about 30 min and the desired compound **19** was isolated in 76% yield. Now, it became clear from these experiments (Table 1, entry 1–5) that the use of Ac₂O was essentially required for this reaction to take place. Performing this transformation in the presence of pyridine/Ac₂O at 0 °C (Table 1, entry 6) afforded **19** in 66% yield in about 90 min. However, when the experiment was repeated with Et₃N instead of pyridine at 0 °C, surprisingly there was a spike in yield (91%) and the reaction was completed in only 30 min (Table 1, entry 7).

To test the efficacy of above method (Table 1, entry 8), we conducted another experiment wherein 2-substituted pyridin-3-one **17** was treated with Et₃N/Ac₂O at 0 °C leading to formation of the 2-substituted-3-acetoxy pyridine **20** in 94% yield in about 30 min.

At this juncture, we envisaged that if the strategy for the conversion of 2-substituted 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones into 2-substituted 3-acetoxy-pyridine could be successfully extended for the transformation of 2,4-disubstituted 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones into the 2,4-disubstituted 3-acetoxy-pyridines, it would enable easy access to important substituted pyridine scaffolds like 2,3-disubstituted 4-iodopyridines and enantiopure 2,3-disubstituted 4-pyridinemethanols, which are found in many biologically important molecules including natural products (Figure 1).

Consequently treatment of various enantiopure 2,4-disubstituted 6-hydroxy-1,6-dihydro-2H-pyridin-3-ones **12a–d** with Et₃N/Ac₂O at 0 °C led to the formation of the enantiopure 2,4-disubstituted-3-acetoxy pyridines **21a–d** in good to very good yields (Table 2). The efficacy of the present method was further demonstrated by its successful application for the construction of important substituted 4-iodopyridine scaffolds **22** and **23** from the 4-iodo-6-hydroxy-1,6-dihydro-2H-pyridin-3-one **16** and **18**, respectively (entry 5, Table 2).

Here, the plausible mechanistic pathway for the formation of functionalized pyridines is proposed to initiate by the acetylation of the C-6 hydroxyl group in pyridine-3-one **6** with Et₃N⁺COCH₃ to generate species **I**. The concomitant cycloelimination of the N-tosyl group and the acetoxy group at C-6 position in **I** led to the formation of pyridone intermediate **II** and acetic 4-methylbenzenesulfonic anhydride **III**.⁶⁷ The enolization of C-3 carbonyl functionality of the intermediate **II** followed by acetyl protection of the resulting enol **IV** ultimately furnished the 3-acetoxy pyridine derivative. The stability of the pyridine moiety compared with the pyridone seems to be the driving force behind the proposed mechanistic pathway (Figure 3).

Further, to support our proposed mechanism that acid anhydride was essentially required to obtain the substituted pyridines from their respective 6-hydroxy-1,6-dihydro-2H-pyridin-3-one, the treatment of 2-substituted 4-iodo-6-hydroxy-1,6-dihydro-2H-pyridin-3-one **18** with Tf₂O/Et₃N in place of Ac₂O/Et₃N led to the formation of 2-substituted 4-iodo-3-trifloxy-pyridine **24** in 84% yield (Scheme 5).

Having these results in our hand, we also became interested to explore the possibility of one-pot synthesis of 4-

Table 2. Transformation of Pyridin-3-ones 12a–d, 16, and 18 into Corresponding Pyridines 21a–d, 22, and 23

Entry	Pyridin-3-one	Pyridine	Time (min)	Yield%
1			30	84
2			30	82
3			30	70 ^a
4			30	86
5			30	89
6			30	93

^aYield calculated over two steps.

iodopyridines directly from 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones. Thus, when 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones **6** and **17** were treated with I₂ in pyridine/CCl₄ until the completion of α-iodination (TLC) followed by stirring of the respective reaction mixture with Ac₂O for 30 min, 4-iodopyridine derivatives **22** and **23** were obtained in 67% and 71% yields, respectively, in a sequential one-pot fashion (Scheme 6).

Further, we are also interested to show that the TBS- and TBDPS-protected pyridines **21a** and **23** were successfully deprotected with TBAF in THF to obtain their analogous hydroxy derivatives **25** and **26** in good yields (Scheme 7). The






Figure 3. Plausible mechanism.

Scheme 5^a




^aReagents and conditions: (a) Tf₂O, Et₃N, -78 °C → RT, 1.5 h, 84%.

Scheme 6^a



^aReagents and conditions: (a) I₂, CCl₄, pyridine, -5 °C → 0 °C, 2 h; (b) Ac₂O, 0 °C, 30 min.

Scheme 7^a



^aReagents and conditions: (a) TBAF, THF, 0 °C → RT, 1 h, 75%; (b) TBAF, THF, 0 °C → RT, 1 h, 70%.


molecules of type **25** could be further utilized as synthetic intermediates for their transformation to medicinally important

fused aromatic ring systems like highly substituted azafluorenes.^{68,69}

Synthesis of 2,7-Disubstituted Furo[2,3-*c*]pyridines.

Acetoxyhalopyridines^{30,31} are widely used for the synthesis of medicinally important molecules like furopyridines^{30,31} and naphthopyridines.⁷⁰ Herein, the synthetic potential of 3-acetoxy-4-iodopyridine **23** has been demonstrated by its chemical transformation to 2,7-disubstituted furo[2,3-*c*]pyridines **28** as illustrated in Scheme 8. Thus, Sonogashira reaction of 3-

Scheme 8^a



^aReagents and conditions: (a) phenylacetylene, Pd[(PPh₃)₂Cl₂], CuI, Et₃N, THF, RT, 2.5 h, 78%; (b) MeOH/Et₃N/H₂O (4:1:1), RT, 12 h, 62%.

acetoxy-substituted 4-iodopyridine **23** gave alkynylpyridine **27**, which on cycloisomerization with MeOH/Et₃N/H₂O furnished the furopyridine **28**.


Synthesis of 7,7'-Disubstituted 2,2'-Bifuro[2,3-*c*]pyridines. Bifuropyridines are another useful class of molecules, but unlike furopyridines there are only a few reports for their synthesis.^{35,36} To further highlight the importance of our above method toward the synthesis of different types of highly substituted pyridine molecules, we have devised an efficient method for the synthesis of 7,7'-disubstituted 2,2'-bifuro[2,3-*c*]pyridine **33** from 2-substituted 3-acetoxy-4-iodopyridine **23**. The schematic representation for its synthesis is delineated in Scheme 9. Thus, heterocoupling of alkynylpyridines **30** and **31** led to bis-alkynylpyridines **32**, which on cycloisomerization gave bifuropyridine **33**.

It is worth mentioning here that 3-hydroxy-4-alkynylpyridines are unstable compounds that cyclize spontaneously to furo[2,3-*c*]pyridines and thus cannot be used as building blocks for further synthesis.³⁰ However, our method as discussed above for the synthesis of substituted pyridines allows direct access to 3-acetoxy-4-iodopyridine obviating the need for protection of 3-hydroxy-4-iodopyridine before proceeding with Sonogashira reaction to obtain the corresponding 4-alkynylpyridine derivatives.

CONCLUSION

In summary, herein an innovative new method to access enantiopure 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones starting from *D*-glucal by utilizing aza-Achmatowicz chemistry has been described. These highly functionalized enantiopure 1,6-dihydro-2*H*-pyridin-3-ones would serve as useful building blocks for the synthesis of diverse types of important enantiopure nitrogen-containing synthetic and natural molecules. We have also disclosed a Et₃N/Ac₂O-mediated mild and novel method for the rapid transformation of 2-substituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones and 2,4-disubstituted 6-hydroxy-1,6-dihydro-2*H*-pyridin-3-ones into 2,3-disubstituted and 2,3,4-trisubstituted pyridines permitting facile access to key pyridine building blocks like 2-substituted 3-

Scheme 9^a



^aReagents and conditions: (a) trimethylsilylacetylene, Pd[(PPh₃)₂Cl₂], CuI, Et₃N, THF, RT, 2.5 h, 82%; (b) NaHCO₃, I₂, MeOH, RT, 24 h, 64%; (c) TBAF, THF, -20 °C, 20 min, 75%; (d) Pd[(PPh₃)₂Cl₂], Et₃N, THF, RT, 2.5 h, 83%; (e) MeOH/Et₃N/H₂O (4:1:1), RT, 18 h, 66%.

acetoxy-4-iodopyridines and enantiopure 2-substituted 3-acetoxy-4-pyridinemethanols possessing benzylic stereogenic centers.

The utilization of commercially available sugars as starting materials, mild reaction conditions, catalytic transfer hydrogen- (CTH) of α -furfuryl azide derivatives, transfer of chiral aryl/alkyl methanols from enulosides to pyridin-3-ones and pyridines, high yields, and short reaction times are the salient features of the present methodology to obtain various pyridones and pyridines that would find wide applications for the synthesis of biologically important molecules. The new methodology is also amenable to easy scale-up. Further work toward the synthesis of highly functionalized novel aza-sugars from 2,4,6-trisubstituted 1,6-dihydro-2*H*-pyridin-3-ones is presently underway.

EXPERIMENTAL SECTION

General Remarks. Organic solvents were dried by standard methods. Analytical TLC was performed using 2.5 × 5 cm² plates coated with a 0.25 mm thickness of silica gel (60 F-254) to monitor all the reactions, and visualization was accomplished with CeSO₄ or 10% H₂SO₄/EtOH and subsequent charring over a hot plate. Silica gel (60–120), (100–200), and (230–400) were used for column chromatography. All the column-purified products were characterized by ¹H NMR, ¹³C NMR, distortionless enhancement by polarization transfer (DEPT) pulse sequence, two-dimensional homonuclear correlation spectroscopy (COSY), heteronuclear single quantum correlation (HSQC), IR, HRMS (direct analysis in real time, DART), and HRMS (quadrupole time of flight, Q-TOF). All NMR spectra were recorded with spectrometers at 300 MHz (¹H) and 75 MHz (¹³C). Experiments were recorded in CDCl₃. Chemical shifts are given on the δ scale. For ¹³C NMR, reference CDCl₃ appeared at 77.40 ppm. Optical rotations were determined by using a 1 dm cell in chloroform or methanol as solvent at 25 °C unless otherwise stated;

concentrations mentioned are in g/100 mL. IR spectra were recorded on FT-IR spectrophotometer.

Compound 4: To a stirred solution of furfuryl alcohol **3** (300 mg, 1.4 mmol) and diphenylphosphoryl azide (DPPA) (0.36 mL, 1.68 mmol) in dry toluene (10 mL) at 0 °C was added DBU (0.25 mL, 1.68 mmol) dropwise over a period of 0.5 h. The reaction mixture was stirred for another 2.5 h at 0 °C and for an additional 21 h at room temperature. After completion of the reaction (TLC), the reaction mixture was washed with water (5 mL) and 1 N HCl (2 × 5 mL), and the organic layer was washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure to yield the crude product mixture. The crude product was chromatographed to furnish the pure compound **4**: yield (250 mg, 74%); oil; *R*_f = 0.50 (hexane/ethyl acetate, 90:10); eluent for column chromatography (hexane/ethyl acetate, 97:3); [α]_D³⁰ = -118.47 (*c* 0.15, CHCl₃). IR (neat, cm⁻¹): 2923, 2357, 2109, 1593, 1734, 1645. ¹H NMR (CDCl₃, 300 MHz): δ 7.43 (s, 1H), 6.37 (s, 2H), 4.77–4.71 (m, 1H), 4.40–4.37 (m, 2H), 1.20 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 178.3 (qC), 149.3 (qC), 143.6 (CH), 110.8 (CH), 109.2 (CH), 64.6 (CH₂), 57.6 (CH), 39.2 (qC), 27.4 (3 × CH₃). HRMS (DART): calcd for C₁₁H₁₆N₃O₃ [M + H]⁺ 238.1191; found 238.1183.

Compound 5: To a solution of compound **4** (250 mg, 1.05 mmol) in CH₃OH (6 mL) was added 10% Pd–C (40 mg) under N₂, and the resulting mixture was subjected to hydrogenation under 1 bar pressure for 45 min. The reaction mixture was filtered through a Celite bed and washed with CH₃OH (3 × 3 mL). The solvents were removed under reduced pressure to obtain the crude product. It was dissolved in dry CH₂Cl₂ (5 mL), and Et₃N (0.22 mL, 1.58 mmol) was added to it at 0 °C followed by dropwise addition of p-TsCl (300 mg, 1.58 mmol) dissolved in dry CH₂Cl₂ over a period of 0.5 h. The reaction mixture was now stirred at room temperature for an additional 2.5 h. On completion of the reaction (TLC), the reaction was quenched with saturated aqueous NaHCO₃ and extracted with dichloromethane (2 × 5 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure to yield the crude product mixture, which on subjection to flash column chromatography furnished the pure compound **5**: yield (330 mg, 78% over two steps); oil; *R*_f = 0.44 (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 92:8); [α]_D²⁹ = -98.51 (*c* 0.15, CHCl₃). IR (neat, cm⁻¹): 2965, 2359, 1723, 1647. ¹H NMR (CDCl₃, 300 MHz): δ 7.67–7.62 (m, 2H), 7.23 (s, 1H), 7.19–7.17 (m, 2H), 6.15 (dd, 1H, *J* = 2.8, *J* = 4.9 Hz), 6.00 (d, 1H, *J* = 4.9 Hz), 5.17 (d, 1H, *J* = 12.5 Hz), 4.79–4.69 (m, 1H), 4.35 (dd, 1H, *J* = 9.4, *J* = 16.9 Hz), 4.17 (dd, 1H, *J* = 8.3, *J* = 16.9 Hz), 2.38 (s, 3H), 1.12 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 178.4 (qC), 150.4 (qC), 143.7 (qC), 142.7 (CH), 137.9 (qC), 129.9 (2 × CH), 127.3 (2 × CH), 110.5 (CH), 108.3 (CH), 64.8 (CH₂), 51.2 (CH), 39.1 (qC), 27.4 (3 × CH₃), 21.8 (CH₃). HRMS (DART): calcd for C₁₈H₂₄N₁O₅S₁ [M + H]⁺ 366.1375; found 366.1380.

Compound 6: NBS (219 mg, 1.23 mmol) was added in small portions over 0.5 h to a stirred solution of *N*-furfurylsulfonamide **5** (300 mg, 1.82 mmol) and NaOAc·3H₂O (145 mg, 1.06) in THF/H₂O (10 mL, 4:1, v/v) at -5 °C, and the reaction mixture was allowed to warm to 0 °C. After completion of the reaction in about 3 h (TLC), the reaction mixture was diluted with ethyl acetate (10 mL) and washed successively with a saturated aqueous solution of KI, Na₂S₂O₃, and NaHCO₃. The organic layer was separated, washed with brine solution, dried over Na₂SO₄, and concentrated *in vacuo* at reduced temperature to furnish the crude product mixture, which was subjected to flash column chromatography to obtain the pure compound **6**: yield (260 mg, 83%); oil; *R*_f = 0.37 (hexane/ethyl acetate, 70:30); eluent for column chromatography (hexane/ethyl acetate, 90:10); [α]_D²⁷ = +10.53 (*c* 0.70, CHCl₃). IR (neat, cm⁻¹): 3406, 2372, 1696, 1348, 1161. ¹H NMR (CDCl₃, 300 MHz): δ 7.64 (d, 2H, *J* = 8.3 Hz), 7.28 (d, 2H, *J* = 8.3), 6.86 (dd, 1H, *J* = 4.5, *J* = 10.3 Hz), 6.03 (dd, 1H, *J* = 1.0, *J* = 10.3 Hz), 5.87–5.84 (m, 1H), 4.63–4.60 (m, 1H), 4.51 (dd, 1H, *J* = 6.0, *J* = 6.2, *J* = 11.2 Hz), 4.39 (dd, 1H, *J* = 5.3, *J* = 11.2 Hz), 3.70 (d, OH, *J* = 5.5 Hz), 2.40 (s, 2H), 1.19 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 191.6 (C=O), 178.4 (qC), 144.8 (qC), 144.3 (CH), 136.6 (qC), 130.5 (2 × CH), 127.5 (CH), 127.0 (2 × CH),

73.4 (CH), 65.5 (CH₂), 59.7 (CH), 39.1 (qC), 27.4 (3 × CH₃), 21.9 (CH₃). HRMS (DART): calcd for C₁₈H₂₂N₁O₅S₁ [M - OH]⁺ 364.1218; found 364.1232.

Compound 7b: To a stirred solution of TBAI (247 mg, 0.67 mmol) in dry DCM (25 mL) at -78 °C was added TiCl₄ (5 mmol, 0.55 mL) dropwise. After stirring for 5 min, a mixture containing 2,3-dideoxy-hex-2-enopyranosid-4-ulose **1** (1.0 g, 3.35 mmol) and 4-(trifluoromethyl)benzaldehyde (0.9 mL, 6.7 mmol) in dry DCM (15 mL) was added. The reaction mixture was allowed to warm to -30 °C and stirred for 5 h. The reaction mixture was quenched with saturated aqueous solution of NaHCO₃ and filtered through a Celite pad. The organic layer was separated from the filtrate, and the aqueous layer was extracted with dichloromethane (2 × 10 mL). The combined organic layers were washed with brine solution, dried over Na₂SO₄, and subjected to column chromatography to obtain the pure compound **7b**: yield (1.2 g, 76%); oil; *R*_f = 0.42 (hexane/ethyl acetate, 12:5); eluent for column chromatography (hexane/ethyl acetate, 21:4); [α]_D²⁹ = -21.28 (*c* 0.1, CHCl₃). IR (neat, cm⁻¹): 3458, 2962, 172, 1467, 1326. ¹H NMR (CDCl₃, 300 MHz): δ 7.60 (d, 1H, *J* = 8.1 Hz), 7.4 (d, 1H, *J* = 8.1 Hz), 6.65–6.64 (m, 1H), 5.62 (s, 1H), 5.29–5.28 (m, 1H), 4.61 (dd, 1H, *J* = 2.7, *J* = 5.2), 4.49 (dd, 1H, *J* = 2.7, *J* = 11.9), 4.41 (dd, 1H, *J* = 5.3, *J* = 11.9), 3.87–3.80 (m, 1H), 3.61–3.53 (m, 1H), 1.69–1.63 (m, 1H), 1.51–1.48 (m, 2H), 1.12 (s, 9H), 0.90 (d, 6H, *J* = 6.6). ¹³C NMR (CDCl₃, 75 MHz): δ 195.0 (C=O), 178.4 (qC), 144.6 (qC), 140.4 (CH), 139.2 (qC), 130.8 (qC), 130.3 (qC), 127.4 (2 × CH), 126.2 (qC), 125.9–125.8 (2 × CH), 122.5 (qC), 93.7 (CH), 72.9 (CH), 71.1 (CH), 68.5 (CH₂), 62.9 (CH₂), 39.1 (qC), 38.6 (CH₂), 27.4 (3 × CH₃), 25.4 (CH), 23.0 (CH₃), 22.8 (CH₃). HRMS (DART): calcd for C₂₄H₃₀F₃O₅ [M - OH]⁺ 455.2045; found 455.2042.

General Procedure for the Synthesis of Compounds 8a–c from 7a–c. **Compound 8a:** 2,6-Lutidine (1 mL, 9.32 mmol) was added at 0 °C to a solution of 2,3-dideoxy-hex-2-enopyranoside alcohol **7a** (2.0 g, 4.66 mmol) in dry CH₂Cl₂ (20 mL), followed by dropwise addition of TBSOTf (1.6 mL, 6.99 mmol) with a syringe, in argon atmosphere, and the mixture was stirred for 3 h. After completion of reaction (TLC), the reaction mixture was quenched with saturated aqueous NaHCO₃ solution (10 mL), and the aqueous layer was extracted with CH₂Cl₂ (2 × 10 mL). The combined organic extracts were dried over Na₂SO₄, concentrated under reduced pressure, and purified by flash column chromatography to furnish the pure compound **8a**: yield (2.1 g, 83%); oil; *R*_f = 0.60 (hexane/ethyl acetate, 90:10); eluent for column chromatography (hexane/ethyl acetate, 97:3); [α]_D²⁷ = -41.66 (*c* 0.1, CHCl₃). IR (neat, cm⁻¹): 3447, 2955, 2363, 2229, 1731, 1632, 1467. ¹H NMR (CDCl₃, 300 MHz): δ 7.57 (d, 2H, *J* = 8.3 Hz), 7.50 (d, 2H, *J* = 8.3 Hz), 7.03–7.02 (m, 1H), 5.61 (s, 1H), 5.34–5.33 (m, 1H), 4.50–4.46 (m, 2H), 4.41–4.35 (m, 1H), 3.85–3.77 (m, 1H), 3.61–3.53 (m, 1H), 1.66–1.62 (m, 1H), 1.52–1.44 (m, 2H), 1.16 (s, 9H), 0.88 (d, 6H, *J* = 6.8), 0.85 (s, 9H), 0.02 (s, 3H), -0.10 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ 193.1 (C=O), 178.3 (qC), 147.8 (qC), 140.6 (qC), 139.2 (CH), 132.4 (2 × CH), 127.9 (2 × CH), 119.1 (qC), 111.8 (CN), 93.9 (CH), 72.89 (CH), 69.6 (CH), 68.4 (CH₂), 62.8 (CH₂), 39.1 (qC), 38.6 (CH₂), 27.4 (3 × CH₃), 26.0 (3 × CH₃), 25.4 (CH), 23.0 (CH₃), 22.8 (CH₃), 18.5 (qC), -4.5 (CH₃), -4.6 (CH₃). HRMS (DART): calcd for C₃₀H₄₆N₁O₆Si₁ [M + H]⁺ 544.3094; found 544.3107.

Compound 8b: Yield (980 mg, 79%); oil; *R*_f = 0.50 (hexane/ethyl acetate, 95:5); eluent for column chromatography (hexane/ethyl acetate, 98.5:1.5); [α]_D³² = -108.21 (*c* 0.1, CHCl₃). IR (neat, cm⁻¹): 2958, 2363, 1735, 1468, 1325. ¹H NMR (CDCl₃, 300 MHz): δ 7.55–7.48 (m, 4H), 7.03–7.02 (m, 1H), 5.65 (s, 1H), 5.35–5.34 (m, 1H), 4.51–4.47 (m, 2H), 4.42–4.36 (m, 1H), 3.86–3.78 (m, 1H), 3.62–3.54 (m, 1H), 1.69–1.63 (m, 1H), 1.51–1.48 (m, 2H), 1.17 (s, 9H), 0.89 (d, 6H, *J* = 6.8), 0.87 (s, 9H), 0.03 (s, 3H), -0.10 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ 193.1 (C=O), 178.3 (qC), 146.4 (qC), 140.9 (qC), 138.9 (CH), 130.7 (qC), 130.2 (qC), 129.8 (qC), 129.4 (qC), 127.5 (2 × CH), 126.3 (qC), 125.5–125.4 (2 × CH), 122.7 (qC), 93.9 (CH), 72.8 (CH), 69.6 (CH), 68.3 (CH₂), 62.8 (CH₂), 39.1 (qC), 38.6 (CH₂), 27.4 (3 × CH₃), 26.0 (3 × CH₃), 25.4 (CH), 23.0 (CH₃), 22.8 (CH₃), 18.5 (qC), -4.5 (CH₃), -4.7 (CH₃). HRMS

(DART): calcd for $C_{25}H_{34}F_3O_5Si_1 [M - C_5H_{11}O]^+$ 499.2127; found 499.2121.

Compound 8c: Yield (1.0 g, 80%); oil; $R_f = 0.55$ (hexane/ethyl acetate, 96:4); eluent for column chromatography (hexane/ethyl acetate, 99:1); $[\alpha]_D^{26} = +87.76$ (c 0.10, $CHCl_3$). IR (neat, cm^{-1}): 3022, 2930, 2361, 1724, 1521, 1467, 1216. 1H NMR ($CDCl_3$, 300 MHz): δ 6.85 (d, 1H, $J = 2.6$), 5.28 (d, 1H, $J = 2.6$), 4.60 (dd, 2H, $J = 2.5$, $J = 5.4$), 4.52 (dd, 1H, $J = 2.6$, $J = 11.9$), 4.43 (dd, 1H, $J = 5.7$, $J = 11.9$), 3.89–3.81 (m, 1H), 3.63–3.55 (m, 1H), 1.74–1.65 (m, 1H), 1.59–1.50 (m, 4H), 1.24 (s, 14H), 1.17 (s, 9H), 0.92–0.89 (m, 18H), 0.03 (s, 3H), –0.04 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ 193.7 (C=O), 178.5 (qC), 141.9 (qC), 139.0 (CH), 94.1 (CH), 72.8 (CH), 68.2 (CH₂), 67.7 (CH), 63.1 (CH₂), 39.1 (qC), 38.7 (CH₂), 37.8 (CH₂), 32.2 (CH₂), 29.9–29.6 (4 × CH₂), 27.5 (3 × CH₃), 26.2 (3 × CH₃), 25.5 (CH), 25.3 (2 × CH₂), 23.0 (CH₃), 22.8 (CH₃), 18.8 (qC), 14.4 (CH₃), –4.2 (CH₃), –4.6 (CH₃). HRMS (DART): calcd for $C_{27}H_{49}O_5Si_1 [M - C_5H_{11}O]^+$ 481.3349; found 481.3355.

Compound 8d: Imidazole (1.294 g, 18.92 mmol) was added at 0 °C to a solution of enone 7d (4.0 g, 12.195 mmol) in dry CH_2Cl_2 (30 mL), followed by the addition of TBSCl (2.012 g, 13.41 mmol). The resulting mixture was stirred for an additional 2 h at room temperature. After completion of the reaction (TLC), the reaction mixture was quenched with saturated aqueous NH_4Cl solution (15 mL) and extracted with CH_2Cl_2 (2 × 10 mL). The combined organic extracts were dried (Na_2SO_4), concentrated under reduced pressure, and purified by flash column chromatography to furnish the pure compound 8d: yield (4.0 g, 74%); oil; $R_f = 0.57$ (hexane/ethyl acetate, 95:5); eluent for column chromatography (hexane/ethyl acetate, 99:1); $[\alpha]_D^{31} = +13.52$ (c 0.10, $CHCl_3$). IR (neat, cm^{-1}): 3427, 3021, 2361, 1725, 1216. 1H NMR ($CDCl_3$, 300 MHz): δ 6.84–6.81 (m, 1H), 5.28–5.27 (m, 1H), 4.60–4.57 (m, 1H), 4.54–4.49 (m, 1H), 4.41–4.33 (m, 3H), 3.87–3.82 (m, 1H), 3.62–3.57 (m, 1H), 1.74–1.68 (m, 1H), 1.54–1.48 (m, 2H), 1.18 (s, 9H), 0.94–0.92 (m, 15H), 0.09 (s, 6H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ 193.9 (C=O), 178.4 (qC), 138.0 (qC), 137.8 (CH), 94.1 (CH), 72.9 (CH), 68.2 (CH₂), 63.2 (CH₂), 58.9 (CH₂), 39.1 (qC), 38.7 (CH₂), 27.4 (3 × CH₃), 26.2 (3 × CH₃), 25.4 (CH), 23.0–22.8 (2 × CH₃), 18.6 (qC), –5.1 (2 × CH₃). HRMS (DART): calcd for $C_{23}H_{43}O_6Si_1 [M + H]^+$ 443.2828; found 443.2832.

General Procedure for the Synthesis of Compounds 9a–d from 8a–d. **Compound 9a:** To a stirred solution of 8a (2.0 g, 3.68 mmol) in ethanol (15 mL) at –5 °C were added $CeCl_3 \cdot 7H_2O$ (685 mg, 1.84 mmol) and $NaBH_4$ (68 mg, 1.84 mmol), and the reaction mixture was stirred for another 1.5 h at the same temperature. After completion of the reaction (TLC), excess $NaBH_4$ was neutralized with acetone, and the solvent was removed under reduced pressure to afford the crude product mixture, which was dissolved in ethyl acetate, filtered through silica gel, and concentrated under reduced pressure to give the crude product. To a stirred solution of the crude product mixture in dry THF (15 mL) were added $ZrCl_4$ (5 mol %) and ZnI_2 (10 mol %), and the resulting reaction mixture was stirred at 60 °C until completion of the reaction (TLC). The mixture was now quenched with water and extracted with ethyl acetate (4 × 10 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated under reduced pressure to afford the crude product. It was then chromatographed to afford pure compound 9a: yield (1.245 g, 74%); oil; $R_f = 0.41$ (hexane/ethyl acetate, 85:15); eluent for column chromatography (hexane/ethyl acetate, 95:5); $[\alpha]_D^{32} = +68.45$ (c 0.1, $CHCl_3$). IR (neat, cm^{-1}): 3427, 2927, 2365, 2231, 1724, 1612, 1435. 1H NMR ($CDCl_3$, 300 MHz): δ 7.59 (d, 2H, $J = 8.3$ Hz), 7.53 (d, 2H, $J = 8.3$ Hz), 7.26 (d, 1H, $J = 1.5$ Hz), 6.24 (d, 1H, $J = 1.7$ Hz), 5.97 (s, 1H), 4.40 (dd, 1H, $J = 7.4$, $J = 11.6$ Hz), 4.33 (dd, 1H, $J = 4.3$, $J = 11.6$ Hz), 2.89 (s, OH), 1.19 (s, 9H), 0.90 (s, 9H), 0.04 (s, 3H), 0.01 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ 179.0 (qC), 150.0 (qC), 147.7 (qC), 142.5 (CH), 132.5 (2 × CH), 126.9 (2 × CH), 126.3 (qC), 119.2 (qC), 111.2 (CN), 110.4 (CH), 68.9 (CH), 66.9 (CH₂), 66.0 (CH), 39.2 (qC), 27.4 (3 × CH₃), 26.1 (3 × CH₃), 18.5 (qC), –4.4 (CH₃), –4.6 (CH₃). HRMS (DART): calcd for $C_{23}H_{35}N_1O_5Si_1 [M]^+$ 457.2284; found 457.2292.

Compound 9b: Yield (575 mg, 71%); oil; $R_f = 0.46$ (hexane/ethyl acetate, 90:10); eluent for column chromatography (hexane/ethyl acetate, 99:1); $[\alpha]_D^{31} = +93.90$ (c 0.1, $CHCl_3$). IR (neat, cm^{-1}): 3448, 2364, 1724, 1325. 1H NMR ($CDCl_3$, 300 MHz): δ 7.58–7.55 (m, 4H), 7.25 (d, 1H, $J = 1.5$ Hz), 6.27 (d, 1H, $J = 1.7$ Hz), 5.98 (s, 1H), 5.10 (dd, 1H, $J = 4.3$, $J = 6.6$ Hz), 4.42 (dd, 1H, $J = 7.7$, $J = 11.5$ Hz), 4.33 (dd, 1H, $J = 4.4$, $J = 11.5$ Hz), 2.95 (s, OH), 1.19 (s, 9H), 0.92 (s, 9H), 0.04–0.03 (m, 6H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ 179.0 (qC), 148.6 (qC), 147.7 (qC), 142.3 (CH), 130.3 (qC), 129.9 (qC), 129.5 (qC), 129.1 (qC), 126.7 (qC), 126.5 (2 × CH), 125.7–125.5 (2 × CH), 122.7 (qC), 110.6 (CH), 69.2 (CH), 66.8 (CH), 65.9 (CH₂), 39.1 (qC), 27.4 (3 × CH₃), 26.1 (3 × CH₃), 18.5 (qC), –4.4 (CH₃), –4.6 (CH₃). HRMS (DART): calcd for $C_{25}H_{34}F_3O_4Si_1 [M - OH]^+$ 483.2178; found 483.2195.

Compound 9c: Yield (519 mg, 68%); oil; $R_f = 0.50$ (hexane/ethyl acetate, 90:10); eluent for column chromatography (hexane/ethyl acetate, 98:2); $[\alpha]_D^{28} = +65.87$ (c 0.10, $CHCl_3$). IR (neat, cm^{-1}): 3448, 2929, 2858, 2372, 1724, 1466. 1H NMR ($CDCl_3$, 300 MHz): δ 7.30–7.29 (m, 1H), 6.32–6.31 (m, 1H), 5.06 (s, 1H), 4.77–4.72 (m, 1H), 4.42 (dd, 1H, $J = 7.9$, $J = 11.4$ Hz), 4.34 (dd, 1H, $J = 4.4$, $J = 11.4$ Hz), 3.09 (d, OH, $J = 5.3$ Hz), 1.75–1.68 (m, 2H), 1.28 (s, 14H), 1.24 (s, 9H), 0.91 (s, 12H), 0.10 (s, 6H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ 178.9 (qC), 147.6 (qC), 141.6 (CH), 127.1 (qC), 110.8 (CH), 68.7 (CH), 67.1 (CH₂), 66.0 (CH), 40.4 (CH₂), 39.1 (qC), 32.2 (CH₂), 30.0–29.6 (4 × CH₂), 27.5 (3 × CH₃), 26.2 (3 × CH₃), 25.9 (CH₂), 23.0 (CH₂), 18.5 (qC), 14.4 (CH₃), –4.2 (CH₃), –4.5 (CH₃). HRMS (DART): calcd for $C_{27}H_{51}O_5Si_1 [M + H]^+$ 483.3505; found 483.3506.

Compound 9d: Yield (2.2 g, 66%); oil; $R_f = 0.37$ (hexane/ethyl acetate, 88:12); eluent for column chromatography (hexane/ethyl acetate, 96:4); $[\alpha]_D^{29} = -4.44$ (c 0.10, $CHCl_3$). IR (neat, cm^{-1}): 2950, 2361, 1723, 1473. 1H NMR ($CDCl_3$, 300 MHz): δ 7.25 (s, 1H), 6.26 (s, 1H), 4.97 (br s, 1H), 4.69–4.59 (m, 1H), 4.36 (dd, 1H, $J = 7.4$, $J = 11.3$ Hz), 4.29 (dd, 1H, $J = 5.2$, $J = 11.3$ Hz), 3.31 (br s, OH), 1.17 (s, 9H), 0.92 (s, 9H), 0.11 (s, 6H). ^{13}C NMR ($CDCl_3 + CCl_4$, 75 MHz): δ 178.4 (qC), 149.8 (qC), 141.4 (CH), 122.1 (qC), 111.4 (CH), 66.7 (CH₂), 66.3 (CH₂), 58.1 (CH), 39.2 (qC), 27.6 (3 × CH₃), 26.4 (3 × CH₃), 18.8 (qC), –4.8 (CH₃), –4.9 (CH₃). HRMS (DART): calcd for $C_{18}H_{31}O_4Si_1 [M - OH]^+$ 339.1991; found 339.1982.

General Procedure for the Synthesis of Compounds 10a–d from 9a–d. **Compound 10a:** To a stirred solution of alcohol 9a (1.2 g, 2.62 mmol) and DPPA (1.69 mL, 7.87 mmol) in dry toluene (15 mL) at 0 °C was added DBU (1.17 mL, 7.87 mmol) dropwise with a syringe over a period of 0.5 h. The reaction mixture was stirred for another 2.5 h at 0 °C and for an additional 21 h at room temperature. Once the reaction was complete (TLC), the reaction mixture was quenched with water (10 mL) and washed with 1 N HCl (2 × 10 mL). The organic layer was separated, dried over Na_2SO_4 , and concentrated under reduced pressure to afford the crude product mixture. The crude product was chromatographed to furnish the pure compound 10a: yield (974 mg, 77%); oil; $R_f = 0.53$ (hexane/ethyl acetate, 90:10); eluent for column chromatography (hexane/ethyl acetate, 98:2); $[\alpha]_D^{30} = -3.78$ (c 0.1, $CHCl_3$). IR (neat, cm^{-1}): 2960, 2364, 2229, 2109, 1729, 1631. 1H NMR ($CDCl_3$, 300 MHz): δ 7.63 (d, 2H, $J = 8.3$ Hz), 7.49 (d, 2H, $J = 8.2$ Hz), 7.31 (d, 1H, $J = 1.8$ Hz), 6.24 (d, 1H, $J = 1.8$ Hz), 5.82 (s, 1H), 4.97 (dd, 1H, $J = 4.9$, $J = 8.7$ Hz), 4.44 (dd, 1H, $J = 8.8$, $J = 11.5$ Hz), 4.35 (dd, 1H, $J = 4.8$, $J = 11.5$ Hz), 1.20 (s, 9H), 0.90 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz): δ 178.4 (qC), 149.5 (qC), 144.3 (qC), 143.5 (CH), 132.8 (2 × CH), 127.4 (qC), 126.9 (2 × CH), 119.0 (CH), 111.7 (CN), 110.4 (CH), 69.6 (CH), 64.7 (CH₂), 56.2 (CH), 39.2 (qC), 27.4 (3 × CH₃), 26.1 (3 × CH₃), 18.5 (qC), –4.4 (CH₃), –4.5 (CH₃). HRMS (DART): calcd for $C_{25}H_{34}N_4O_4Si_1 [M]^+$ 482.234; found 482.2348.

Compound 10b: Yield (462 mg, 80%); oil; $R_f = 0.56$ (hexane/ethyl acetate, 95:5); eluent for column chromatography (hexane/ethyl acetate, 99.5:0.5); $[\alpha]_D^{27} = -17.73$ (c 0.1, $CHCl_3$). IR (neat, cm^{-1}): 3458, 2365, 2110, 1728, 1325. 1H NMR ($CDCl_3$, 300 MHz): δ 7.59 (d, 2H, $J = 8.1$ Hz), 7.50 (d, 2H, $J = 8.1$ Hz), 7.30 (d, 2H, $J = 1.6$ Hz), 6.26 (d, 1H, $J = 1.6$ Hz), 5.86–5.84 (m, 1H), 5.01–4.96 (m, 1H), 4.48–4.37 (m, 1H), 4.36–4.33 (m, 1H), 1.20 (s, 9H), 0.91 (s, 9H),

0.04 (s, 3H), 0.01 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.4 (qC), 148.5 (qC), 144.1 (qC), 143.3 (CH), 130.3 (qC), 129.9 (qC), 129.7 (qC), 127.9 (qC), 126.6 (2 \times CH), 125.9–125.8 (2 \times CH), 121.8 (qC), 110.5 (CH), 69.8 (CH), 64.8 (CH₂), 56.3 (CH), 39.3 (qC), 27.4 (3 \times CH₃), 26.1 (3 \times CH₃), 18.7 (qC), –4.4 (CH₃), –4.5 (CH₃). HRMS (DART): calcd for $\text{C}_{19}\text{H}_{19}\text{F}_3\text{N}_3\text{O}_3$ [$\text{M} - \text{C}_5\text{H}_{13}\text{O}_1\text{Si}_1$]⁺ 394.1378; found 394.1374.

Compound 10c: Yield (400 mg, 76%); oil; R_f = 0.58 (hexane/ethyl acetate, 98:2); eluent for column chromatography (hexane/ethyl acetate, 99:1); [α]_D²⁷ = –13.27 (c 0.10, CHCl_3). IR (neat, cm^{-1}): 2927, 2363, 2110, 1731, 1465, 1217. ^1H NMR (CDCl_3 , 300 MHz): δ 7.31 (d, 1H, J = 1.6 Hz), 6.31 (d, 1H, J = 1.7 Hz), 4.94 (dd, 1H, J = 4.4, J = 8.9 Hz), 4.69–4.65 (m, 1H), 4.48 (dd, 1H, J = 9.0, J = 11.5 Hz), 4.27 (dd, 1H, J = 4.6, J = 11.5 Hz), 1.69–1.60 (m, 2H), 1.25 (s, 14H), 1.22 (s, 9H), 0.88 (s, 12H), 0.60 (s, 3H) –0.05 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.3 (qC), 143.7 (qC), 142.9 (CH), 128.9 (qC), 110.5 (CH), 68.1 (CH), 64.8 (CH₂), 56.3 (CH), 40.7 (CH₂), 39.2 (qC), 32.2 (CH₂), 29.9–29.6 (4 \times CH₂), 27.4 (3 \times CH₃), 26.2 (3 \times CH₃), 25.6 (CH₂), 23.0 (CH₂), 18.5 (qC), 14.4 (CH₃), –4.2 (CH₃), –4.6 (CH₃). HRMS (DART): calcd for $\text{C}_{27}\text{H}_{50}\text{N}_1\text{O}_4\text{Si}_1$ [$\text{M} - \text{N}_2$]⁺ 480.3509; found 480.3507.

Compound 10d: Yield (1.618 g, 72%); oil; R_f = 0.40 (hexane/ethyl acetate, 98:2); eluent for column chromatography (hexane/ethyl acetate, 99:1); [α]_D³¹ = –14.76 (c 0.10, CHCl_3). IR (neat, cm^{-1}): 3020, 2361, 2109, 1726, 1216. ^1H NMR (CDCl_3 , 300 MHz): δ 7.34 (d, 1H, J = 2.6 Hz), 6.30 (d, 1H, J = 2.6 Hz) 5.0 (dd, 1H, J = 8.5, J = 12.2 Hz), 4.63 (s, 2H), 4.43–4.30 (m, 2H), 1.19 (s, 9H), 0.92 (s, 9H), 0.11 (s, 6H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 177.9 (qC), 144.9 (qC), 142.9 (CH), 124.5 (qC), 111.1 (CH), 64.5 (CH₂), 57.7 (CH₂), 56.2 (CH), 39.2 (qC), 27.6 (3 \times CH₃), 26.4 (3 \times CH₃), 18.8 (qC), –4.8 (2 \times CH₃). HRMS (DART): calcd for $\text{C}_{18}\text{H}_{32}\text{N}_3\text{O}_4\text{Si}_1$ [$\text{M} + \text{H}$]⁺ 382.2162; found 382.2159.

General Procedure for the Synthesis of Compounds 11a–d from 10a–d. **Compound 11a:** To a solution of compound 10a (900 mg, 1.86 mmol) in $\text{CH}_3\text{OH}/\text{CHCl}_3$ (12 mL, 5:1, v/v) were added 10% Pd–C (150 mg) and Et_3SiH (0.69 mL, 4.66 mmol) under argon, and the reaction mixture was stirred at room temperature for 2 h. It was filtered through a Celite bed and washed with CH_3OH . The solvents were removed under reduced pressure to obtain the crude product mixture, which was dissolved in dry CH_2Cl_2 (10 mL), and then Et_3N (0.39 mL, 2.8 mmol) was added to it at 0 °C followed by dropwise addition of $p\text{-TsCl}$ (532 mg, 2.8 mmol) dissolved in dry CH_2Cl_2 over a period of 0.5 h. The reaction mixture was now stirred at room temperature for an additional 2.5 h. On completion of the reaction (TLC), the reaction was quenched with saturated aqueous NaHCO_3 and extracted with dichloromethane (2 \times 5 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated under reduced pressure to yield the crude product mixture. Flash column chromatography gave the pure compound 11a: yield (797 mg, 70%); oil; R_f = 0.48 (hexane/ethyl acetate, 75:25); eluent for column chromatography (hexane/ethyl acetate, 98:2); [α]_D²⁵ = +22.43 (c 0.5, MeOH). IR (neat, cm^{-1}): 2960, 2364, 2229, 2109, 1729, 1631. ^1H NMR (CDCl_3 , 300 MHz): δ 7.58 (d, 2H, J = 8.2 Hz), 7.54–7.45 (m, 4H), 7.13 (d, 1H, J = 9.0 Hz), 7.06 (d, 1H, J = 1.5 Hz), 6.22 (d, 1H, J = 1.6 Hz), 5.77 (s, 1H), 5.34 (d, 1H, J = 8.6 Hz), 5.0–4.93 (m, 1H), 4.16 (dd, 1H, J = 7.3, J = 11.3 Hz), 3.93 (dd, 1H, J = 4.8, J = 11.3 Hz), 2.36 (s, 3H), 1.08 (s, 9H), 0.87 (s, 9H), 0.02 (s, 3H), –0.06 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.3 (qC), 149.7 (qC), 144.9 (qC), 143.4 (qC), 142.5 (CH), 138.3 (qC), 132.6 (2 \times CH), 129.7 (2 \times CH), 127.2 (2 \times CH), 126.8 (2 \times CH), 125.6 (qC) 118.9 (qC), 111.5 (CN) 110.2 (CH), 69.9 (CH), 64.8 (CH₂), 49.8 (CH), 38.9 (qC), 27.2 (3 \times CH₃), 26.0 (3 \times CH₃), 21.7 (CH₃) 18.4 (qC), –4.5 (2 \times CH₃). HRMS (DART): calcd for $\text{C}_{32}\text{H}_{42}\text{N}_2\text{O}_6\text{S}_1\text{Si}_1$ [M]⁺ 610.2532; found 610.2522.

Compound 11b: Yield (380 mg, 68%); oil; R_f = 0.46 (hexane/ethyl acetate, 85:15); eluent for column chromatography (hexane/ethyl acetate, 95:5); [α]_D²⁹ = –13.64 (c 0.1, CHCl_3). IR (neat, cm^{-1}): 3449, 2933, 1725, 1325. ^1H NMR (CDCl_3 , 300 MHz): δ 7.76–7.68 (m, 4H), 7.64 (d, 2H, J = 8.2 Hz), 7.32 (d, 2H, J = 8.0 Hz), 7.26 (d, 1H, J = 1.1 Hz), 6.43 (d, 2H, J = 1.4 Hz), 5.97 (s, 1H), 5.53 (d, 1H, J = 5.8

Hz), 5.20–5.13 (m, 1H), 4.38 (dd, 1H, J = 7.3, J = 11.2 Hz), 4.12 (dd, 1H, J = 4.9, J = 11.2 Hz), 2.54 (s, 3H), 1.27 (s, 9H), 1.08 (s, 9H), 0.23 (s, 3H), 0.13 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.4 (qC), 148.5 (qC), 144.8 (qC), 143.4 (qC), 142.1 (CH), 138.3 (qC), 130.2 (qC), 129.7 (CH), 127.0 (CH), 126.9 (CH), 126.1 (CH), 125.9 (CH), 125.8 (CH), 122.6 (qC), 110.4 (CH), 70.2 (CH), 64.9 (CH₂), 49.9 (CH), 39.0 (qC), 27.3 (3 \times CH₃), 26.1 (3 \times CH₃), 21.7 (CH₃), 18.5 (qC), –4.4 (CH₃), –4.5 (CH₃). HRMS (DART): calcd for $\text{C}_{32}\text{H}_{42}\text{F}_3\text{N}_1\text{O}_6\text{S}_1\text{Si}_1$ [M]⁺ 653.2454; found 653.2456.

Compound 11c: Yield (311 mg, 71%); oil; R_f = 0.40 (hexane/ethyl acetate, 96:4); eluent for column chromatography (hexane/ethyl acetate, 96:4); [α]_D³⁰ = +17.50 (c 0.10, CHCl_3). IR (neat, cm^{-1}): 3274, 2858, 2368, 1724, 1266. ^1H NMR (CDCl_3 , 300 MHz): δ 7.62 (d, 2H, J = 8.2 Hz), 7.18 (d, 2H, J = 8.2 Hz), 7.09 (d, 1H, J = 1.6 Hz), 6.20 (d, 1H, J = 1.6 Hz), 5.23 (d, 1H, J = 8.2 Hz), 4.95 (d, 1H, J = 6.9, J = 13.0 Hz), 4.64–4.60 (m, 1H), 4.29 (dd, 1H, J = 7.0, J = 11.2 Hz), 4.07 (dd, 1H, J = 5.0, J = 11.2 Hz), 2.37 (s, 3H), 1.62–1.59 (m, 2H), 1.24 (s, 14H), 1.13 (s, 9H), 0.87 (s, 12H), 0.04 (s, 3H), –0.09 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.5 (qC), 144.4 (qC), 143.4 (CH), 141.6 (CH), 138.4, 129.9 (qC), 129.8 (CH), 127.4, 127.1 (CH), 127.0 (qC), 126.9 (qC), 110.8 (CH), 68.0 (CH), 65.4 (CH₂), 49.9 (CH), 42.3 (qC), 40.4 (CH₂), 39.1 (qC), 32.2 (CH₂), 29.9–29.7 (4 \times CH₂), 27.4 (3 \times CH₃), 26.2 (2 \times CH₃), 25.7 (CH₂), 23.0 (CH₂), 21.8 (CH₃), 14.5 (CH₃), –4.2 (CH₃) –4.6 (CH₃). HRMS (DART): calcd for $\text{C}_{34}\text{H}_{57}\text{N}_1\text{O}_6\text{S}_1\text{Si}_1$ [M]⁺ 635.3675; found 635.3659.

Compound 11d: Yield (1.6 g, 75%); oil; R_f = 0.34 (hexane/ethyl acetate, 85:15); eluent for column chromatography (hexane/ethyl acetate, 90:10); [α]_D²⁹ = –2.03 (c 0.10, CHCl_3). IR (neat, cm^{-1}): 3430, 3019, 2363, 1592, 1217. ^1H NMR (CDCl_3 , 300 MHz): δ 7.57 (d, 2H, J = 8.2 Hz), 7.13 (d, 2H, J = 8.0 Hz), 7.04 (d, 1H, J = 1.6 Hz), 6.03 (d, 1H, J = 1.59 Hz), 5.68 (d, 1H, J = 9.0 Hz), 4.91–4.83 (m, 1H), 4.45–4.41 (m, 1H), 4.34–4.27 (m, 1H), 4.20–4.15 (m, 1H), 2.34 (s, 3H), 1.12 (s, 9H), 0.92 (s, 9H), 0.11 (s, 6H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.4 (qC), 146.3 (qC), 143.3 (qC), 141.6 (CH), 138.0 (qC), 129.6 (2 \times CH), 127.1 (2 \times CH), 122.1 (qC), 110.8 (CH), 64.8 (CH₂), 57.9 (CH₂), 50.2 (CH), 39.1 (qC), 27.4 (3 \times CH₃), 26.3 (3 \times CH₃), 21.8 (CH₃), 18.7 (qC), –5.0 (2 \times CH₃). HRMS (DART): calcd for $\text{C}_{25}\text{H}_{40}\text{N}_1\text{O}_6\text{S}_1\text{Si}_1$ [$\text{M} + \text{H}$]⁺ 510.2345; found 510.2337.

General Procedure for the Synthesis of Compounds 12a–d from 11a–d. **Compound 12a:** NBS (437 mg, 2.45 mmol) was added in small portions over 0.5 h to solution of $p\text{-toluenesulfonyl}$ amine 11a (750 mg, 1.22 mmol) in $\text{THF}-\text{H}_2\text{O}$ (10 mL, 4:1, v/v) cooled to –5 °C, and the reaction mixture was allowed to warm to room temperature. After completion of the reaction in about 3.5 h (TLC), the reaction mixture was diluted with ethyl acetate (10 mL) and washed successively with a saturated aqueous solution of KI, $\text{Na}_2\text{S}_2\text{O}_3$, and NaHCO_3 . The organic layer was separated, washed with brine solution, dried over Na_2SO_4 , and concentrated *in vacuo* at reduced temperature to furnish the crude mixture, which was subjected to flash column chromatography to give the pure compound 12a: yield (507 mg, 66%); oil; R_f = 0.33 (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 90:10); [α]_D³¹ = +5.79 (c 0.1, CHCl_3). IR (neat, cm^{-1}): 2923, 2357, 1728, 1596, 1216. ^1H NMR (CDCl_3 , 300 MHz): δ 7.64 (d, 2H, J = 8.2), 7.54 (d, 2H, J = 8.2), 7.43 (d, 2H, J = 8.2), 7.28–7.26 (m, 2H), 7.05 (d, 1H, J = 3.7), 5.98 (d, 1H, J = 3.6), 5.52 (s, 1H), 4.56–4.52 (m, 1H), 4.27 (dd, 1H, J = 6.0, J = 11.3), 4.1 (dd, 1H, J = 6.6, J = 11.3), 2.39 (s, 1H), 0.95 (s, 9H), 0.78 (s, 9H) –0.13 (s, 3H), –0.18 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 190.7 (C=O), 177.9 (qC), 147.3 (qC), 144.7 (qC), 140.3 (qC), 139.1 (CH), 136.7 (qC), 132.5 (2 \times CH), 130.5 (2 \times CH), 127.6 (2 \times CH), 127.0 (2 \times CH), 118.9 (qC), 111.9 (CN), 73.9 (CH) 69.3 (CH), 64.8 (CH₂), 59.4 (CH), 38.9 (qC), 27.2 (3 \times CH₃), 25.9 (3 \times CH₃), 21.8 (CH₃), 18.3 (qC), –4.7 (CH₃), –4.9 (CH₃). HRMS (DART): calcd for $\text{C}_{32}\text{H}_{41}\text{N}_2\text{O}_6\text{S}_1\text{Si}_1$ [$\text{M} - \text{OH}$]⁺ 609.2454; found 609.2463.

Compound 12b: Yield (98 mg, 64%); oil; R_f = 0.46 (hexane/ethyl acetate, 86:14); eluent for column chromatography (hexane/ethyl acetate, 95:5); [α]_D²⁹ = +7.86 (c 0.2, CHCl_3). IR (neat, cm^{-1}): 2921, 2363, 1732, 1218. ^1H NMR (CDCl_3 , 300 MHz): δ 7.76–7.70 (m,

4H), 7.64 (d, 2H, $J = 8.25$), 7.32 (d, 2H, $J = 8.04$), 7.26 (d, 1H, $J = 1.08$), 6.43 (d, 2H, $J = 1.44$), 5.97 (s, 1H), 5.53 (d, 2H, $J = 5.8$), (dd, 1H, $J = 4.8$, $J = 8.5$), 4.38 (dd, 1H, $J = 7.2$, $J = 10.11$), 4.12 (dd, 1H, $J = 4.86$, $J = 11.2$), 1.27 (s, 9H), 1.08 (s, 9H), 0.23 (s, 6H), 0.13 (s, 6H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 190.6 (C=O), 177.9 (qC), 144.8 (qC), 140.9 (qC), 138.7 (CH), 136.8 (CH), 130.5 (2 \times CH), 127.2 (2 \times CH), 127.1 (CH), 125.7 (CH), 125.6 (CH), 74.0 (CH), 69.4 (CH), 65.1 (CH₂), 59.4 (CH), 38.9 (qC), 27.3 (3 \times CH₃), 27.1 (3 \times CH₃), 21.7 (CH₃), 18.5 (qC), -4.6 (CH₃), -4.8 (CH₃). HRMS (DART): calcd for $\text{C}_{32}\text{H}_{41}\text{F}_3\text{N}_1\text{O}_6\text{S}_1\text{Si}_1$ [$\text{M} - \text{OH}$]⁺ 652.2375; found 652.2387.

Compound 12d: Yield (1.284 g, 83%); oil; $R_f = 0.33$ (hexane/ethyl acetate, 85:15); eluent for column chromatography (hexane/ethyl acetate, 99:1); $[\alpha]_D^{30} = +9.48$ (c 0.10, CHCl_3). IR (neat, cm^{-1}): 3425, 2924, 2369, 1722, 1591, 1217. ^1H NMR (CDCl_3 , 300 MHz): δ 7.64 (d, 1H, $J = 8.3$ Hz), 7.28–7.26 (m, 2H), 6.87–6.84 (m, 1H), 5.92 (br s, 1H), 4.59–4.46 (m, 1H), 4.49 (dd, 1H, $J = 5.8$, $J = 11.2$ Hz), 4.38 (dd, 1H, $J = 6.0$, $J = 11.2$ Hz), 4.24–4.23 (m, 2H), 3.65 (br s, OH), 2.39 (s, 3H), 1.16 (s, 9H), 0.88 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 191.4 (C=O), 178.2 (qC), 144.7 (qC), 137.8 (qC), 137.6 (CH), 136.8 (qC), 130.4 (2 \times CH), 127.2 (2 \times CH), 74.2 (CH), 65.8 (CH₂), 59.6 (CH), 59.2 (CH), 39.2 (qC), 27.4 (3 \times CH₃), 26.1 (3 \times CH₃), 21.9 (CH₃), 18.8 (qC), -5.1 (CH₃), -5.2 (CH₃). HRMS (DART): calcd for $\text{C}_{23}\text{H}_{38}\text{N}_1\text{O}_6\text{S}_1\text{Si}_1$ [$\text{M} - \text{OH}$]⁺ 508.2189; found 508.2181.

Compound 13: To a solution of 2,3-dideoxy-hex-2-enopyranosid-4-ulose **1** (600 mg, 2.0 mmol) in CCl_4 /pyridine at -5°C (1:1, 14 mL), a solution of iodine (2.147 g, 8.45 mmol) in CCl_4 /pyridine (1:1, 14 mL) was added dropwise under argon. Subsequently, the reaction mixture was allowed to warm to 10°C and stirred for 2 h. On completion of reaction (TLC), the reaction mixture was diluted with ether (30 mL) and washed successively with water (20 mL), HCl (1 N, 2 \times 20 mL), water (20 mL), and saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$ solution (12 mL). The organic layer was separated, washed with brine solution, dried over Na_2SO_4 , and evaporated *in vacuo* at room temperature to obtain the crude product. Column chromatographic purification of the crude product furnished the pure compound **13**: yield (750 mg, 88%); $R_f = 0.44$ (hexane/ethyl acetate, 92:8); eluent for column chromatography (hexane/ethyl acetate, 96:4); $[\alpha]_D^{30} = +9.86$ (c 0.05, MeOH). IR (neat, cm^{-1}): 2926, 2362, 1728, 1596, 1219. ^1H NMR (CDCl_3 , 300 MHz): δ 7.59 (d, 1H, $J = 3.8$ Hz), 5.11 (d, 1H, $J = 3.8$ Hz), 4.85 (dd, 1H, $J = 2.7$, $J = 5.4$ Hz), 4.55 (dd, 1H, $J = 2.6$, $J = 11.9$ Hz), 4.46 (dd, 1H, $J = 5.5$, $J = 11.9$ Hz), 3.85–3.80 (m, 1H), 3.61–3.56 (m, 1H), 1.74–1.65 (m, 1H), 1.57–1.49 (m, 1H), 1.17 (s, 9H), 0.91 (d, 6H, $J = 6.5$ Hz). ^{13}C NMR (CDCl_3 , 75 MHz): δ 187.7 (C=O), 178.3 (qC), 153.2 (CH), 102.7 (qC), 95.3 (CH), 73.4 (CH), 68.4 (CH₂), 63.4 (CH₂), 39.1 (qC), 38.6 (CH₂), 27.5 (3 \times CH₃), 25.3 (3 \times CH), 22.9 (CH₃), 22.8 (CH₃). HRMS (DART): calcd for $\text{C}_{16}\text{H}_{26}\text{I}_1\text{O}_5$ [$\text{M} + \text{H}$]⁺ 425.0824; found 425.0833.

The Protocol Adopted for the Synthesis of 15 from 14 Was Similar to the Synthesis of 4 from 3. **Compound 15:** Yield (157 mg, 81%); oil; $R_f = 0.45$ (hexane/ethyl acetate, 95:05); eluent for column chromatography (hexane/ethyl acetate, 99.5:0.5); $[\alpha]_D^{29} = +1.16$ (c 0.10, MeOH). IR (neat, cm^{-1}): 2357, 2106, 1642. ^1H NMR (CDCl_3 , 300 MHz): δ 7.43 (d, 1H, $J = 1.9$ Hz), 6.49 (d, 1H, $J = 1.9$ Hz), 4.89 (dd, 1H, $J = 6.3$, $J = 7.6$ Hz), 4.45 (dd, 1H, $J = 7.7$, $J = 11.2$ Hz), 4.33 (dd, 1H, $J = 6.2$, $J = 11.2$ Hz), 1.19 (s, 9H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.2 (qC), 150.1 (qC), 145.0 (CH), 118.3 (CH), 66.9 (qC), 63.9 (CH₂), 56.4 (CH), 39.2 (qC), 27.4 (3 \times CH₃). HRMS (DART): calcd for $\text{C}_{11}\text{H}_{14}\text{I}_1\text{O}_3$ [$\text{M} - \text{N}_3$]⁺ 320.9987; found 320.9983.

Compound 16: To a stirred solution of pyridone **6** (400 mg, 1.04 mmol) in CCl_4 /pyridine (1:1, 8 mL), dropwise addition of a solution of iodine (1.12 g, 4.41 mmol) in CCl_4 /pyridine (1:1, 8 mL) was done under argon at -5°C . Subsequently, the reaction mixture was allowed to warm to 0°C and stirred for 2 h. On completion of the reaction (TLC), the reaction mixture was diluted with ether (20 mL) and washed successively with water (12 mL), HCl (1 N, 2 \times 12 mL), water (12 mL), and saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$ solution (8 mL). The organic layer was separated, washed with brine solution, dried over

Na_2SO_4 , and evaporated *in vacuo* at room temperature to obtain the crude product. Its column chromatography furnished the pure compound **16**: yield (400 mg, 75%); oil; $R_f = 0.40$ (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 90:10); $[\alpha]_D^{26} = -4.30$ (c 0.19 MeOH). IR (neat, cm^{-1}): 2961, 2376, 1716, 1589, 1346. ^1H NMR (CDCl_3 , 300 MHz): δ 7.64 (d, 2H, $J = 8.3$ Hz), 7.58 (d, 2H, $J = 4.8$ Hz), 7.30 (d, 2H, $J = 8.0$), 4.88–4.84 (m, 1H), 4.50 (dd, 1H, $J = 6.0$, $J = 6.2$, $J = 11.4$ Hz), 4.39 (dd, 1H, $J = 5.4$, $J = 11.4$ Hz), 2.41 (s, 2H), 1.18 (s, 9H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 185.6 (C=O), 178.2 (qC), 152.7 (qC), 145.2 (CH), 136.2 (qC), 130.6 (2 \times CH), 127.1 (CH), 102 (qC), 75.8 (CH), 65.6 (CH₂), 59.1 (CH), 39.1 (qC), 27.4 (3 \times CH₃), 21.9 (CH₃). HRMS (DART): calcd for $\text{C}_{18}\text{H}_{21}\text{I}_1\text{N}_1\text{O}_3\text{S}_1$ [$\text{M} - \text{OH}$]⁺ 490.0185; found 490.0192.

Compound 18: A solution of iodine (399 mg, 1.6 mmol) in CCl_4 /pyridine (1:1, 4 mL) was added dropwise under argon at -5°C to a solution of **17** (200 mg, 0.4 mmol) in CCl_4 /pyridine (1:1, 4 mL). Subsequently the reaction mixture was allowed to warm to 0°C and stirred for 3 h, 30 min. On completion of reaction (TLC), the reaction mixture was diluted with ether (20 mL) and washed successively with water (10 mL), HCl (1 N, 2 \times 10 mL), water (10 mL), and saturated sodium thiosulfate solution (10 mL). The worked-up product was dried over Na_2SO_4 , evaporated at reduced pressure and temperature, and codistilled with toluene. Column chromatography furnished pure compound **18**: yield (200 mg, 81%); solid; mp 48–50 $^\circ\text{C}$; $R_f = 0.50$ (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 96:4); $[\alpha]_D^{21} = -22.62$ (c 0.30, MeOH). IR (KBr, cm^{-1}): 3365, 2931, 2363, 1695, 1354. ^1H NMR (CDCl_3 , 300 MHz): δ 7.79–7.75 (m, 2H), 7.46–7.38 (m, 6H), 7.43–7.35 (m, 6H), 5.98 (dd, 1H, $J = 5.3$, $J = 11.9$ Hz), 5.17 (d, 1H, $J = 11.9$ Hz), 4.80 (s, 1H), 3.83 (dd, 1H, $J = 2.4$, $J = 11.0$ Hz), 3.52 (dd, 1H, $J = 1.8$, $J = 11.0$ Hz), 2.45 (s, 3H), 0.94 (s, 9H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 186.9 (C=O), 154.9 (CH), 144.6 (qC), 137.7 (qC), 136.1 (2 \times CH), 135.6 (2 \times CH), 131.3 (qC), 130.9 (qC), 130.6 (2 \times CH), 130.3 (2 \times CH), 128.4 (2 \times CH), 128.3 (2 \times CH), 127.8 (2 \times CH), 104.0 (qC), 75.1 (CH), 65.4 (CH₂), 61.8 (CH), 27.1 (3 \times CH₃), 22.0 (CH₃), 19.4 (qC). HRMS (DART): calcd for $\text{C}_{29}\text{H}_{31}\text{I}_1\text{N}_1\text{O}_4\text{S}_1\text{Si}_1$ [$\text{M} - \text{OH}$]⁺ 644.0787; found 644.0806.

Compound 19: To a solution of the pyridone **6** (100 mg, 0.26 mmol) in Et_3N (5 mL) at 0°C was added Ac_2O (0.074 mL, 0.79 mmol), and the resulting mixture was allowed to stir for 0.5 h at the same temperature. Et_3N and Ac_2O were removed at reduced pressure, and the residue obtained was purified by column chromatography to furnish the pure compound **19**: yield (60 mg, 91%); oil; $R_f = 0.40$ (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 92:8). IR (neat, cm^{-1}): 1731, 1645, 1200. ^1H NMR (CDCl_3 , 300 MHz): δ 8.09 (d, 1H, $J = 5.0$ Hz), 7.76 (d, 1H, $J = 5.0$ Hz), 7.26 (s, 1H), 5.17 (s, 2H), 2.38 (s, 3H), 1.20 (s, 9H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 178.4 (qC), 169.0 (qC), 148.5 (qC), 147.1 (CH), 131.0 (CH), 124.6 (CH), 63.3 (CH₂), 39.2 (qC), 27.5 (3 \times CH₃), 21.2 (CH₃). HRMS (ESI): calcd for $\text{C}_{13}\text{H}_{18}\text{N}_1\text{O}_4$ [$\text{M} + \text{H}$]⁺ 252.1236; found 252.1246.

Similarly Compound 20 Was Synthesized from 17. **Compound 20:** Yield (1.494 g, 94%); oil; $R_f = 0.42$ (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 92:8). IR (neat, cm^{-1}): 1768, 1638, 1214. ^1H NMR (CDCl_3 , 300 MHz): δ 8.47–8.46 (m, 1H), 7.73–7.71 (m, 4H), 7.47–7.37 (m, 7H), 7.31–7.28 (m, 1H), 4.86 (s, 2H), 2.19 (s, 3H), 1.07 (s, 9H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 169.0 (qC), 151.9 (qC), 146.7 (CH), 146.2 (qC), 136.0 (4 \times CH), 133.7 (qC), 130.9 (CH), 130.0 (2 \times CH), 128.0 (4 \times CH), 123.8 (CH), 64.7 (CH₂), 27.1 (3 \times CH₃), 21.2 (CH₃), 19.6 (qC). HRMS (DART): calcd for $\text{C}_{24}\text{H}_{28}\text{N}_1\text{O}_3\text{Si}_1$ [$\text{M} + \text{H}$]⁺ 406.1838; found 406.1804.

General Procedure for the Synthesis of Compounds 21a–d from 12a–d. **Compound 21a:** To a solution of the pyridone **12a** (150 mg, 0.239 mmol) in Et_3N (2 mL) at 0°C was added Ac_2O (0.068 mL, 0.71 mmol), and the resulting mixture was allowed to stir for 0.5 h at the same temperature. Et_3N and Ac_2O were removed at reduced pressure, and the residue obtained was purified by column chromatography to furnish the pure compound **21a**: yield (88 mg,

84%); oil; $R_f = 0.45$ (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 93:7); $[\alpha]_D^{31} = +108.75$ (c 0.1, CHCl₃). IR (neat, cm⁻¹): 2928, 2365, 2230, 1774, 1732, 1368. ¹H NMR (CDCl₃, 300 MHz): δ 8.50 (d, 1H, $J = 4.9$), 7.61 (d, 2H, $J = 8.2$), 7.50 (d, 1H, $J = 4.8$), 7.41 (d, 2H, $J = 8.2$), 5.79 (s, 1H), 5.15 (d, 1H, $J = 12.4$), 5.09 (d, 1H, $J = 12.3$), 2.29 (s, 3H), 1.17 (s, 9H), 0.89 (s, 9H), -0.01 (s, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ 178.2 (qC), 168.3 (qC), 149.6 (qC), 147.7 (CH), 145.8 (qC), 145.8 (qC), 143.0 (qC), 132.6 (2 × CH), 127.3 (2 × CH), 122.5 (CH), 118.8 (qC), 112.0 (CN), 70.5 (CH), 65.3 (CH₂), 39.1 (qC), 27.4 (3 × CH₃), 26.0 (3 × CH₃), 21.0 (CH₃), 18.5 (qC), -4.64 (CH₃), -4.7 (CH₃). HRMS (DART): calcd for C₂₇H₃₇N₂O₅Si₁ [M + H]⁺ 497.2471; found 497.2473.

Compound 21b: Yield (17 mg, 82%); oil; $R_f = 0.44$ (hexane/ethyl acetate, 86:14); eluent for column chromatography (hexane/ethyl acetate, 94:6); $[\alpha]_D^{27} = +18.64$ (c 0.1, CHCl₃). IR (neat, cm⁻¹): 2921, 1727, 1627, 1218. ¹H NMR (CDCl₃, 300 MHz): δ 8.50 (d, 1H, $J = 4.9$ Hz), 7.55 (d, 3H, $J = 6.8$ Hz), 7.40 (d, 2H, $J = 8.04$ Hz), 5.81 (s, 1H), 5.12 (d, 2H, $J = 3.3$ Hz), 2.28 (s, 3H), 1.18 (s, 9H), 0.85 (s, 9H), -0.002 (s, 3H), -0.01 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ 178.3 (qC), 168.4 (qC), 149.5 (qC), 147.7 (CH), 146.5 (qC), 146.3 (qC), 143.1 (qC), 130.6 (2 × CH), 125.8 (CH), 125.7 (CH), 122.5 (CH), 70.7 (CH), 63.4 (CH₂), 39.1 (qC), 27.4 (3 × CH₃), 26.0 (3 × CH₃), 21.0 (CH₃), 18.5 (qC), -4.6 (CH₃), -4.7 (CH₃). HRMS (DART): calcd for C₂₇H₃₇F₃N₁O₅Si₁ [M + 1]⁺ 540.2393; found 540.2394.

Compound 21c: Yield (23 mg, 70% over two steps); oil; $R_f = 0.56$ (hexane/ethyl acetate, 90:10); eluent for column chromatography (hexane/ethyl acetate, 97:3); $[\alpha]_D^{29} = +15.85$ (c 0.20, MeOH). IR (neat, cm⁻¹): 2929, 2363, 1598, 1215. ¹H NMR (CDCl₃, 300 MHz): δ 8.45 (d, 1H, $J = 5.0$ Hz), 7.46 (d, 1H, $J = 5.0$ Hz), 5.16 (s, 1H), 4.68 (dd, 1H, $J = 4.7$, $J = 6.8$ Hz), 2.32 (s, 3H), 1.62 (s, 2H), 1.24 (s, 14H), 1.19 (s, 9H), 0.87 (s, 12H), -0.02 (s, 3H), -0.15 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ 178.4 (qC), 168.6 (qC), 148.7 (qC), 148.3 (qC), 147.3 (CH), 142.9 (qC), 122.7 (CH), 68.7 (CH), 63.6 (CH₂), 39.2 (qC), 39.0 (CH₂), 32.2 (CH₂), 29.9 (CH₂), 29.8–29.6 (3 × CH₂), 27.5 (3 × CH₃), 26.1 (3 × CH₃), 25.1 (CH₂), 23.0 (CH₂), 20.9 (CH₃), 18.4 (qC), 14.4 (CH₃), -4.4 (CH₃), -4.8 (CH₃). HRMS (DART): calcd for C₂₉H₃₂N₁O₅Si₁ [M + H]⁺ 522.3614; found 522.3608.

Compound 21d: Yield (45 mg, 85%); oil; $R_f = 0.55$ (hexane/ethyl acetate, 85:15); eluent for column chromatography (hexane/ethyl acetate, 95:5). IR (neat, cm⁻¹): 2924, 2372, 1730, 1462, 1214, 761. ¹H NMR (CDCl₃, 300 MHz): δ 8.48 (d, 1H, $J = 4.8$ Hz), 7.51 (d, 1H, $J = 4.8$ Hz), 5.17 (s, 2H), 4.61 (s, 2H), 2.32 (s, 3H), 1.19 (s, 9H), 0.94 (s, 9H), 0.09 (s, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ 178.7 (qC), 168.8 (qC), 148.2 (qC), 147.6 (CH), 144.3 (qC), 122.6 (CH), 63.4 (CH₂), 59.6 (CH₂), 39.2 (qC), 27.5 (3 × CH₃), 26.2 (3 × CH₃), 20.8 (CH₃), 18.7 (qC), -5.1 (2 × CH₃). HRMS (DART): calcd for C₂₀H₃₄N₁O₅Si₁ [M + H]⁺ 396.2206; found 396.2196.

Compound 22: To a solution of **16** (120 mg, 0.24 mmol) in Et₃N (3 mL) at 0 °C was added Ac₂O (0.067 mL, 0.71 mmol), and the resulting mixture was allowed to stir for 0.5 h at the same temperature. Et₃N and Ac₂O were removed at reduced pressure, and the residue obtained was purified by column chromatography to furnish the pure compound **22**: yield (79 mg, 89%); oil; $R_f = 0.35$ (hexane/ethyl acetate, 85:15); eluent for column chromatography (hexane/ethyl acetate, 93:7). IR (neat, cm⁻¹): 2927, 2362, 1720, 1217. ¹H NMR (CDCl₃, 300 MHz): δ 8.09 (d, 1H, $J = 5.0$ Hz), 7.75 (d, 1H, $J = 5.0$ Hz), 5.17 (s, 2H), 2.37 (s, 3H), 1.2 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 178.3 (qC), 167.9 (qC), 149.8 (qC), 147.6 (CH), 134.9 (CH), 104.0 (qC), 63.6 (CH₂), 39.2 (qC), 27.5 (3 × CH₃), 21.4 (CH₃). HRMS (DART): calcd for C₁₃H₁₇I₁N₁O₄ [M + H]⁺ 378.0202; found 378.0196.

Similarly Compound 23 Was Synthesized from 18. **Compound 23:** Yield (150 mg, 93%); oil; $R_f = 0.48$ (hexane/ethyl acetate, 85:15); eluent for column chromatography (hexane/ethyl acetate, 97:3). IR (neat, cm⁻¹): 2927, 1774, 1557, 1215. ¹H NMR (CDCl₃, 300 MHz): δ 8.06 (d, 1H, $J = 5.0$ Hz), 7.72–7.70 (m, 5H), 7.46–7.37 (m, 6H), 4.80 (s, 2H), 2.24 (s, 3H), 1.08 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 167.8 (qC), 153.1 (qC), 147.8 (qC), 147.2 (CH), 136.0 (4 ×

CH), 134.2 (CH), 133.5 (qC), 130.1 (2 × CH), 128.0 (4 × CH), 104.0 (qC), 65.2 (CH₂), 27.1 (3 × CH₃), 21.3 (CH₃), 19.6 (qC). HRMS (ESI): calcd for C₂₄H₂₇I₁N₁O₃Si₁ [M + H]⁺ 532.0805; found 532.0769.

Compound 24: Et₃N (0.15 mL, 1.09 mmol) and Tf₂O (0.14 mL, 0.82 mmol) were added dropwise under N₂ atmosphere to the solution of 4-iodopyridone **18** (180 mg, 0.27 mmol) in DCM (5 mL) cooled to -78 °C with continuous stirring, and the resulting mixture was allowed to reach room temperature. After 1.5 h, the reaction mixture was quenched with saturated aqueous NH₄Cl and extracted with DCM (3 × 5 mL). The combined organic layers were washed with brine solution, dried over Na₂SO₄, and evaporated *in vacuo* to obtain the crude reaction mixture. Column chromatography of the crude mixture furnished the pure compound **24**: yield (142 mg, 84%); oil; $R_f = 0.50$ (hexane/ethyl acetate, 90:10); eluent for column chromatography (hexane/ethyl acetate, 99:1). IR (neat, cm⁻¹): 2929, 1622, 1418, 1218. ¹H NMR (CDCl₃, 300 MHz): δ 8.14 (d, 1H, $J = 4.9$ Hz), 7.73 (d, 1H, $J = 4.9$ Hz), 7.64 (d, 4H, $J = 7.5$ Hz), 7.42–7.33 (m, 6H), 4.98 (s, 2H), 1.07 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 154.4 (qC), 149.1 (CH), 145.4 (qC), 135.9 (4 × CH), 135.4 (CH), 133.2 (CH), 130.1 (2 × CH), 128.0 (4 × CH), 101.8 (qC), 64.2 (CH₂), 27.1 (3 × CH₃), 19.6 (qC). HRMS (DART): calcd for C₂₃H₂₄F₃I₁N₁O₄S₁Si₁ [M + 1]⁺ 622.0192; found 622.0194.

Compound 25: TBAF (0.2 mL, 0.2 mmol) was added at 0 °C to a solution of 4-pyridylalcohol **21a** (88 mg, 0.23 mmol) in THF (5 mL) with a syringe, and the resulting mixture was stirred for 1 h at room temperature. After completion of the reaction (TLC), the reaction mixture was quenched with saturated aqueous NH₄Cl solution (4 mL), and it was extracted with EtOAc (2 × 5 mL). The combined extracts were dried over (Na₂SO₄), concentrated under reduced pressure, and purified by flash column chromatography to furnish the pure compound **25**: yield (50 mg, 75%); oil; $R_f = 0.42$ (hexane/ethyl acetate, 60:40); eluent for column chromatography (hexane/ethyl acetate, 75:25); $[\alpha]_D^{30} = +26.12$ (c 0.45, MeOH). IR (neat, cm⁻¹): 2926, 2360, 1742, 1427. ¹H NMR (CDCl₃, 300 MHz): δ 8.88 (brs, OH), 8.20 (d, 2H, $J = 4.8$ Hz), 7.60 (d, 2H, $J = 8.2$ Hz), 7.52 (d, 1H, $J = 8.2$ Hz), 7.35 (d, 1H, $J = 4.8$ Hz), 7.16 (s, 1H), 5.25 (d, 1H, $J = 12.1$ Hz), 5.13 (d, 1H, $J = 12.0$ Hz), 2.17 (s, 3H), 1.17 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 182.6 (qC), 169.6 (qC), 149.6 (qC), 144.0 (qC), 142.5 (qC), 142.2 (CH), 137.1 (qC), 132.6 (2 × CH), 128.3 (2 × CH), 122.1 (CH), 118.8 (qC), 112.0 (CN), 70.8 (CH), 65.4 (CH₂), 39.4 (qC), 27.3 (3 × CH₃), 21.0 (CH₃). HRMS (ESI): calcd for C₂₁H₂₃N₂O₅ [M + H]⁺ 383.1607; found 383.1576.

Compound 26: Yield (160 mg, 70%); semisolid; $R_f = 0.41$ (hexane/ethyl acetate, 60:40); eluent for column chromatography (hexane/ethyl acetate, 75:25). IR (KBr, cm⁻¹): 3375, 2363, 1656, 1588, 1111. ¹H NMR (CDCl₃, 300 MHz): δ 7.79 (d, 1H, $J = 4.9$ Hz), 7.68 (d, 1H, $J = 4.9$ Hz), 5.26 (s, 1H), 2.13 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ 174.3 (qC), 152.6 (qC), 142.3 (CH), 141.4 (qC), 135.6 (CH), 98.6 (qC), 65.3 (CH₂), 21.1 (CH₃). HRMS (ESI): calcd for C₈H₉INO₃ [M + H]⁺ 293.9627; found 293.9643.

Compound 27: To a mixture of compound **23** (350 mg, 0.659 mmol), phenyl acetylene (0.036 mL, 0.329 mmol), Pd[Cl₂(PPh₃)₂] (46 mg, 0.065 mmol), and CuI (12 mg, 0.065 mmol) in 10 mL of THF under N₂ atmosphere was added Et₃N (0.27 mL, 1.97 mmol), and resulting solution was stirred for 3 h at room temperature. The reaction was diluted with 20 mL of CHCl₃, washed with 1 N HCl (2 × 10 mL), and extracted with CHCl₃ (2 × 5 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, and evaporated *in vacuo* to obtain the crude compound, which was subjected to flash column chromatography to furnish the pure compound **27**: yield (250 mg, 78%); oil; $R_f = 0.45$ (hexane/ethyl acetate, 84:16); eluent for column chromatography (hexane/ethyl acetate, 94:6). IR (neat, cm⁻¹): 2927, 2366 1772, 1645, 1216. ¹H NMR (CDCl₃, 300 MHz): δ 8.43 (d, 1H, $J = 4.9$ Hz), 7.73–7.71 (m, 4H), 7.53–7.50 (m, 2H), 7.44–7.37 (m, 10H), 4.82 (s, 2H), 2.25 (s, 3H), 1.06 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 168.2 (qC), 152.8 (qC), 146.7 (qC), 146.6 (CH), 136.0 (4 × CH), 133.6 (qC), 132.1 (2 × CH), 130.0 (2 × CH), 129.8 (CH), 128.9 (2 × CH), 128.0 (4 × CH), 126.7 (qC), 126.1 (CH), 122.2 (qC), 98.6 (qC), 82.7 (qC), 64.8 (CH₂), 27.1 (3 ×

CH₃), 20.9 (CH₃), 19.6 (qC). HRMS (ESI): calcd for C₃₂H₃₂N₁O₃Si₁ [M + H]⁺ 506.2152; found 506.2128.

Compound 28: A solution of compound 27 (70 mg, 0.138 mmol) in MeOH–Et₃N–H₂O (2 mL, 4:1:1), was allowed to stir at room temperature for 12 h. The reaction mixture was diluted with EtOAc (5 mL) and then extracted with EtOAc (2 × 2 mL). The combined extracts were washed with brine solution, dried over Na₂SO₄, and evaporated under reduced pressure to obtain the crude residue. Its flash chromatography furnished the pure compound 28: yield (40 mg, 62%); oil; R_f = 0.35 (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 93:7). IR (neat, cm⁻¹): 2361, 1648, 1544, 1216. ¹H NMR (CDCl₃, 300 MHz): δ 8.35 (d, 1H, J = 5.2 Hz), 7.784–7.78 (m, 4H), 7.45–7.43 (m, 4H), 7.40–7.35 (m, 6H), 7.01 (s, 1H), 5.20 (s, 2H), 1.09 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 159.0 (qC), 150.6 (qC), 144.0 (qC), 142.3 (CH), 136.5 (qC), 136.1 (4 × CH), 133.8 (qC), 130.1 (qC), 130.0 (2 × CH), 129.8 (CH), 129.2 (2 × CH), 128.0 (4 × CH), 126.1 (2 × CH), 115.6 (CH), 100.7 (CH), 64.9 (CH₂), 27.2 (CH₃), 19.7 (qC). HRMS (DART): calcd for C₃₀H₃₀N₁O₂Si₁ [M + H]⁺ 464.2045; found 464.2063.

Compound 29: A mixture of 23 (400 mg, 0.75 mmol), (trimethylsilyl)acetylene (0.13 mL, 0.97 mmol), bis-(triphenylphosphine) palladium dichloride (52 mg, 0.08 mmol), and CuI (14 mg, 0.08 mmol) in 10 mL of THF under N₂ was treated with Et₃N (0.3 mL, 2.25 mmol) and was stirred for 3 h at room temperature. The reaction was diluted with 20 mL of CHCl₃ and was washed with 2 × 10 mL of 1 N HCl. The combined aqueous layers were extracted with CHCl₃ (2 × 5 mL) and dried over Na₂SO₄; flash column chromatography furnished desired compound 29: yield (310 mg, 82%); oil; R_f = 0.51 (hexane/ethyl acetate, 88:12); eluent for column chromatography (hexane/ethyl acetate, 96:4). IR (neat, cm⁻¹): 2321, 1775, 1426, 1217. ¹H NMR (CDCl₃, 300 MHz): δ 8.38 (d, 1H, J = 4.9 Hz), 7.70–7.68 (m, 4H), 7.42–7.35 (m, 6H), 7.30 (d, 1H, J = 4.9 Hz), 4.77 (s, 2H), 2.20 (s, 3H), 1.03 (s, 9H), 0.25 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 168.0 (qC), 152.7 (qC), 146.6 (CH), 136.0 (4 × CH), 133.6 (qC), 130.0 (2 × CH), 128.0 (4 × CH), 126.4 (qC), 126.3 (CH), 105.2 (qC), 97.6 (qC), 64.7 (CH₂), 27.1 (3 × CH₃), 20.9 (CH₃), 19.6 (qC), 0.0 (3 × CH₃). HRMS (ESI): calcd for C₂₉H₃₆N₁O₃Si₂ [M + H]⁺ 502.2234; found 502.2202.

Compound 30: TBAF (0.33 mL, 0.33 mmol) was added at –30 °C to a solution of compound 29 (150 mg, 0.30 mmol) in THF (5 mL), and the reaction mixture was allowed to stir for 20 min. On completion of the reaction (TLC), the reaction mixture was quenched with saturated aqueous NH₄Cl and extracted with DCM (3 × 5 mL). The organic layers were washed with brine solution, dried over Na₂SO₄, and concentrated under reduced pressure to afford the crude residue, which was purified by flash chromatography to furnish the compound 30: yield (90 mg, 70%); solid; mp 70 °C; R_f = 0.43 (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 96:4). IR (KBr, cm⁻¹): 2925, 2364, 1632, 1218. ¹H NMR (CDCl₃, 300 MHz): δ 8.41 (d, 1H, J = 4.9 Hz), 7.70–7.68 (m, 4H), 7.42–7.34 (m, 6H), 4.79 (s, 2H), 3.42 (s, 2H), 2.21 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz): δ 168.2 (qC), 153.0 (qC), 147.1 (qC), 146.6 (CH), 136.0 (4 × CH), 133.6 (qC), 130.0 (2 × CH), 128.0 (4 × CH), 126.8 (CH), 125.6 (qC), 86.3 (qC), 77.0 (qC), 64.7 (CH₂), 27.1 (3 × CH₃), 20.9 (CH), 19.6 (qC). HRMS (DART): calcd for C₂₆H₂₈N₁O₃Si₁ [M + H]⁺ 430.1838; found 430.1836.

Compound 31: Iodine (456 mg, 1.80 mmol) and NaHCO₃ (150 mg, 1.80 mmol) were added at room temperature to a stirred solution of compound 29 (200 mg, 0.40 mmol) in MeOH (10 mL), and the resulting mixture was allowed to stir at the same temperature for 24 h. The reaction mixture was diluted with EtOAc (10 mL), washed successively with saturated aqueous Na₂S₂O₃ solution and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by flash chromatography to give compound 31: yield (143 mg, 64%); solid; mp 110–112 °C; R_f = 0.46 (hexane/ethyl acetate, 83:17); eluent for column chromatography (hexane/ethyl acetate, 95:5). IR (KBr, cm⁻¹): 2932, 2370, 1715, 1213. ¹H NMR (CDCl₃, 300 MHz): δ 8.40 (d, 1H, J = 4.9 Hz), 7.71–7.69 (m, 1H), 7.43–7.35 (m, 6H), 7.28 (d, 1H, J = 4.9 Hz), 4.78 (s, 2H), 2.22 (s,

9H). ¹³C NMR (CDCl₃, 75 MHz): δ 168.2 (qC), 152.9 (qC), 147.7 (qC), 146.5 (CH), 136.0 (4 × CH), 133.6 (qC), 130.0 (2 × CH), 128.0 (4 × CH), 126.7 (CH), 126.5 (qC), 87.7 (qC), 64.7 (CH₂), 27.1 (3 × CH₃), 20.9 (CH₃), 19.6 (qC), 18.5 (qC). HRMS (ESI): calcd for C₂₆H₂₇I₁N₁O₃Si₁ [M + H]⁺ 556.0805; found 556.0774.

Compound 32: A mixture of 31 (75 mg, 0.135 mmol), 4-acetylenicpyridine 30 (75 mg, 0.175 mmol), bis(triphenylphosphine) palladium dichloride (9 mg, 0.013 mmol), and CuI (2.4 mg, 0.013 mmol) in 5 mL of THF under N₂ was treated with Et₃N (0.024 mL, 0.175 mmol) and was stirred for 1 h at room temperature. The reaction was diluted with 5 mL of CHCl₃ and was washed with 2 × 2 mL of 1 N HCl. The combined aqueous layers were extracted with CHCl₃ (2 × 2 mL) and dried over Na₂SO₄; flash column chromatography furnished desired compound 32: yield (96 mg, 83%); oil; R_f = 0.40 (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 90:10). IR (Neat, cm⁻¹): 2925, 2341, 1777, 1592. ¹H NMR (CDCl₃, 300 MHz): δ 8.44 (d, 2H, J = 4.9 Hz), 7.70–7.67 (m, 9H), 7.43–7.36 (m, 15H), 4.80 (s, 4H), 2.24 (s, 6H), 1.05 (s, 18H). ¹³C NMR (CDCl₃, 75 MHz): δ 168.2 (2 × qC), 153.3 (2 × qC), 147.4 (2 × qC), 146.7 (2 × CH), 136.0 (8 × CH), 133.5 (2 × qC), 130.1 (4 × CH), 128.0 (8 × CH), 126.7 (2 × CH), 124.8 (2 × qC), 80.9 (2 × qC), 77.1 (2 × qC), 64.7 (2 × CH₂), 27.1 (6 × CH₃), 20.9 (2 × CH₃), 19.6 (2 × qC). HRMS (ESI): calcd for C₅₂H₅₃N₂O₆Si₂ [M + H]⁺ 857.3442; found 857.3411.

Compound 33: A solution of compound 32 (50 mg, 0.058 mmol) in MeOH–Et₃N–H₂O (1.6 mL, 4:1:1) was allowed to stir at room temperature for 18 h. The reaction mixture was diluted with EtOAc (5 mL) and then extracted with EtOAc (2 × 2 mL). The combined extracts were washed with brine solution, dried over Na₂SO₄, and evaporated under reduced pressure to obtain the crude residue. Its flash chromatography furnished the pure 33: yield (30 mg, 66%); oil; R_f = 0.40 (hexane/ethyl acetate, 80:20); eluent for column chromatography (hexane/ethyl acetate, 90:10). IR (neat, cm⁻¹): 2931, 2368, 1626, 1369, 1218. ¹H NMR (CDCl₃, 300 MHz): δ 8.39 (d, 2H, J = 5.2 Hz), 7.80–7.77 (m, 8H), 7.47 (d, 2H, J = 5.2 Hz), 7.41–7.34 (m, 12H), 6.96 (s, 2H), 5.23 (s, 4H), 1.12 (s, 18H). ¹³C NMR (CDCl₃, 75 MHz): δ 150.9 (2 × qC), 149.5 (2 × qC), 144.8 (2 × qC), 142.6 (2 × CH), 136.1 (8 × CH), 135.6 (2 × qC), 133.8 (2 × qC), 130.1 (4 × CH), 128.1 (8 × CH), 116.2 (2 × CH), 104.8 (2 × CH), 77.6 (2 × qC), 65.2 (2 × CH₂), 27.2 (6 × CH₃), 19.8 (2 × qC). HRMS (ESI): calcd for C₄₈H₄₉N₂O₄Si₂ [M + H]⁺ 773.3231; found 773.3214.

■ ASSOCIATED CONTENT

📄 Supporting Information

¹H and ¹³C NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: akshaw55@yahoo.com.

■ ACKNOWLEDGMENTS

The authors are grateful to Sophisticated Analytical Instrument Facility (SAIF), CDRI Lucknow, India, for providing spectral data, Mr. R. K. Purshottam for providing HPLC data, and Mr. Anoop K. Pandey for technical assistance. I.H. thanks Council of Scientific and Industrial Research (CSIR), New Delhi, India, for financial support. A DST Grant (No. SR/SI/OC-17/2010) to support the work described in this manuscript is gratefully acknowledged. CDRI communication no. is 8135.

■ REFERENCES

- (1) Bobrov, D. N.; Tyvorskii, V. I. *Tetrahedron* **2010**, *66*, 5432–5434.
- (2) Aida, W.; Ohtsuki, T.; Li, X.; Ishibashi, M. *Tetrahedron* **2009**, *65*, 369–373.

- (3) Soman, A. G.; Gloer, J. B.; Angawi, R. F.; Wicklow, D. T.; Dowd, P. F. *J. Nat. Prod.* **2001**, *64*, 189–192.
- (4) (a) Bagley, M. C.; Dale, J. W.; Merritt, E. A.; Xiong, X. *Chem. Rev.* **2005**, *105*, 685–714, and references cited therein. (b) Nicolaou, K. C.; Safina, B. S.; Zak, M.; Lee, S. H.; Nevalainen, M.; Bella, M.; Estrada, A. A.; Funke, C.; Zécri, F. J.; Bulat, S. *J. Am. Chem. Soc.* **2005**, *127*, 11159–11175.
- (5) Atta-ur-Rahman; Shahwar, D.; Choudhary, M. I.; Sener, B.; Toker, G.; Baser, K. H. C. *Phytochemistry* **1999**, *50*, 333–336.
- (6) Saitton, S.; Kihlberg, J.; Luthmana, K. *Tetrahedron* **2004**, *60*, 6113–6120.
- (7) O'Hagan, D. *Nat. Prod. Rep.* **2000**, *17*, 435–446, and references cited therein.
- (8) Niiyama, K.; Nagase, T.; Fukami, T.; Takezawa, Y.; Takezawa, H.; Hioki, Y.; Takeshita, H.; Ishikawa, K. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 527–532.
- (9) Shaw, S. A.; Aleman, P.; Vedejs, E. *J. Am. Chem. Soc.* **2003**, *125*, 13368–13369.
- (10) Xu, D.-Z.; Shi, S.; Wang, Y. *Eur. J. Org. Chem.* **2009**, 4848–4853.
- (11) Kwong, H.-L.; Yeung, H.-L.; Yeung, C.-T.; Lee, W.-S.; Lee, C.-S.; Wong, W.-L. *Coord. Chem. Rev.* **2007**, *251*, 2188–2222.
- (12) Wurz, R. P. *Chem. Rev.* **2007**, *107*, 5570–5595.
- (13) Spivey, A. C.; Arseniyadis, S. *Angew. Chem., Int. Ed.* **2004**, *43*, 5436–5441.
- (14) Xu, Q.; Wu, X.; Pan, X.; Chan, A. S. C.; Yang, T.-k. *Chirality* **2002**, *14*, 28–31.
- (15) Geormezi, M.; Deimede, V.; Gourdoupi, N.; Triantafyllopoulos, N.; Neophytides, S.; Kallitsis, J. K. *Macromolecules* **2008**, *41*, 9051–9056.
- (16) Yoneyama, H.; Tsujimoto, A.; Goto, H. *Macromolecules* **2007**, *40*, 5279–5283.
- (17) Aubert, P.-H.; Knipper, M.; Groenendaal, L.; Lutsen, L.; Manca, J.; Vanderzande, D. *Macromolecules* **2004**, *37*, 4087–4098.
- (18) Reilly, M.; Anthony, D. R.; Gallagher, C. *Tetrahedron Lett.* **2003**, *44*, 2927–2930.
- (19) Clayden, J.; Hennecke, U. *Org. Lett.* **2008**, *10*, 3567–3570.
- (20) Carreiro, E. D.; Yong-En, G.; Burke, A. J. *J. Mol. Catal. A: Chem.* **2005**, *235*, 285–292.
- (21) Bull, S. D.; Davies, S. G.; Fox, D. J.; Gianotti, M.; Kelly, P. M.; Pierres, C.; Savory, E. D.; Smith, A. D. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1858–1868.
- (22) Cihangir Tanyeli, C.; Akhmedov, I. M.; Işık, M. *Tetrahedron Lett.* **2004**, *45*, 5799–5801.
- (23) Miller, S. P.; Morgan, J. B.; Felix, J.; Nepveux, V.; Morken, J. P. *Org. Lett.* **2004**, *6*, 131–133.
- (24) Uenishi, J.; Hamada, M.; Aburatani, S.; Matsui, K.; Yonemitsu, O.; Tsukube, H. *J. Org. Chem.* **2004**, *69*, 6781–6789.
- (25) Felpin, F.-X.; Vo-Thanh, G.; Villiéras, J.; Lebreton, J. *Tetrahedron: Asymmetry* **2001**, *12*, 1121–1124.
- (26) Le Strat, F.; Harrowen, D. C.; Maddaluno, J. *J. Org. Chem.* **2005**, *70*, 489–496.
- (27) Li, X.; Yin, W.; Sarma, P. V. V. S.; Zhou, H.; Ma, J.; Cook, J. M. *Tetrahedron Lett.* **2004**, *45*, 8569–8573.
- (28) Lindstro, S.; Ripa, L.; Hallberg, A. *Org. Lett.* **2000**, *2*, 2291–2293.
- (29) Sammakia, T.; Stangeland, E. L.; Whitcomb, M. C. *Org. Lett.* **2002**, *4*, 2385–2388.
- (30) Yue, D.; Yao, T.; Larock, R. C. *J. Org. Chem.* **2005**, *70*, 10292–10296, and references cited therein.
- (31) Arcadi, A.; Cacchi, S.; Giuseppe, S. D.; Fabrizi, G.; Marinelli, F. *Org. Lett.* **2002**, *4*, 2409–2412, and references cited therein.
- (32) Buckmelter, A. J.; Ren, L.; Laird, E. R.; Rast, B.; Miknis, G.; Wenglowksy, S.; Schlachter, S.; Welch, M.; Tarlton, E.; Grina, J.; Lyssikatos, J.; Brandhuber, B. J.; Morales, T.; Randolph, N.; Vigers, G.; Martinson, M.; Callejo, M. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1248–1252.
- (33) Arcadi, A.; Cacchi, S.; Giuseppe, S. D.; Fabrizi, G.; Marinelli, F. *Synlett* **2002**, 453–457.
- (34) Wishka, D. G.; Graber, D. R.; Seest, E. P.; Dolak, L. A.; Han, F.; Watt, W.; Morris, J. *J. Org. Chem.* **1998**, *63*, 7851–7859.
- (35) Chartoire, A.; Comoy, C.; Fort, Y. *J. Org. Chem.* **2010**, *75*, 2227–2235.
- (36) Lechel, T.; Dash, J.; Brüdgam, I.; Reißig, H.-U. *Eur. J. Org. Chem.* **2008**, 3647–3655.
- (37) Maloney, K. M.; Nwakpuda, E.; Kuethe, J. T.; Yin, J. *J. Org. Chem.* **2009**, *74*, 5111–5114.
- (38) Coudret, C. *Synth. Commun.* **1996**, *26*, 3543–3547.
- (39) Coombs, T. C.; Lee, M. D. IV; Wong, H.; Armstrong, M.; Cheng, B.; Chen, W.; Moretto, A. F.; Liebeskind, L. S. *J. Org. Chem.* **2008**, *73*, 882–888.
- (40) Couladouros, E. A.; Strongilos, A. T.; Neokosmidis, E. *Tetrahedron Lett.* **2007**, *48*, 8227–8229.
- (41) Cassidy, M. P.; Padwa, A. *Org. Lett.* **2004**, *6*, 4029–4031.
- (42) Haukaas, M. H.; O'Doherty, G. A. *Org. Lett.* **2001**, *3*, 401–404.
- (43) Koulocheri, S. D.; Magiatis, P.; Haroutounian, S. A. *J. Org. Chem.* **2001**, *66*, 7915–7918.
- (44) Zhou, W.-S.; Lu, Z.-H.; Xu, Y.-M.; Liao, L.-X.; Wang, Z.-M. *Tetrahedron* **1999**, *55*, 11959–11983.
- (45) Koulocheri, S. D.; Haroutounian, S. A. *Synthesis* **1999**, 1889–1892.
- (46) Zhao, H.; Holladay, J. E.; Brown, H.; Zhang, Z. C. *Science* **2007**, *316*, 1597–1600, and references cited therein.
- (47) Hollingsworth, R. I.; Wang, G. *Chem. Rev.* **2000**, *100*, 4267–4282, and references cited therein.
- (48) Yim, H.-K.; Wong, H. N. C. *J. Org. Chem.* **2004**, *69*, 2892–2895.
- (49) Saquib, M.; Husain, I.; Kumar, B.; Shaw, A. K. *Chem.–Eur. J.* **2009**, *15*, 6041–6049.
- (50) (a) Bawa, R. A.; Ajjabou, F.; Shalfooh, E. *J. Phys. Sci.* **2008**, *19*, 1–5. (b) Nakamura, K.; Takenaka, K.; Fujii, M.; Ida, Y. *Tetrahedron Lett.* **2002**, *43*, 3629–3631. (c) Matthew, T. D.; David, P.; Devine, P. *Org. Lett.* **2007**, *9*, 335–338.
- (51) Maerten, E.; Agbossou-Niedercorn, F.; Castanet, Y.; Mortreux, A. *Tetrahedron* **2008**, *64*, 8700–8708.
- (52) Pollet, P.; Turck, A.; Plé, N.; Quéguiner, G. *J. Org. Chem.* **1999**, *64*, 4512–4515.
- (53) Blayo, A.-L.; Meur, S. L.; Gree, D.; Gree, R. *Adv. Synth. Catal.* **2008**, *350*, 471–476.
- (54) Schmidt, L. H.; Crosby, R.; Rasco, J.; Vaughan, D. *Antimicrob. Agents Chemother.* **1978**, *14*, 420–435.
- (55) Thompson, A. S.; Humphrey, G. R.; De Marco, A. M.; Mathre, D. J.; Grabowski, E. J. *J. Org. Chem.* **1993**, *58*, 5886–5888.
- (56) Ostrowski, J.; Altenbach, H.-J.; Wischnat, R.; Brauer, D. *J. Eur. J. Org. Chem.* **2003**, 1104–1110.
- (57) Saquib, M.; Gupta, M. K.; Sagar, R.; Prabhakar, Y. S.; Shaw, A. K.; Kumar, R.; Maulik, P. K.; Gaikwad, A. N.; Sinha, S.; Srivastava, A. K.; Chaturvedi, V.; Srivastava, R.; Srivastava, B. S. *J. Med. Chem.* **2007**, *50*, 2942–2950, and reference cited therein.
- (58) Prestat, G.; Baylon, C.; Heck, M.-P.; Grasa, G. A.; Nolan, S. P.; Mioskowski, C. *J. Org. Chem.* **2004**, *69*, 5770–5773.
- (59) Mandal, P. K.; McMurray, J. S. *J. Org. Chem.* **2007**, *72*, 6599–6601.
- (60) Cheng, K.; Kelly, A. R.; Kohn, R. A.; Dweck, J. F.; Walsh, P. J. *Org. Lett.* **2009**, *11*, 2703–2706.
- (61) Tee, O. S.; Iyengar, R. *Can. J. Chem.* **1990**, *68*, 1769–1773, and references cited therein.
- (62) Recently we have reported the synthesis of enuloside **7d** in 49% yield from enuloside **1** by reacting it with 37% aqueous solution of HCHO in THF in the presence of DMAP at RT in our previous manuscript: Saquib, M.; Husain, I.; Sharma, S.; Yadav, G.; Singh, V. K.; Sharma, S. K.; Shah, P.; Siddiqi, M. I.; Kumar, B.; Lal, J.; Jain, G. K.; Srivastava, B. S.; Srivastava, R.; Shaw, A. K. *Eur. J. Med. Chem.* **2011**, *46*, 2217–2223. However, in the present study the yield of enuloside **7d** was improved from 49% to 62% when enuloside **1** was reacted with 37% aqueous solution of HCHO in THF in the presence of DMAP at –10 °C instead of at RT.
- (63) Faucher, N.; Ambroise, Y.; Cintrat, J.-C.; Doris, E.; Pillon, F.; Rousseau, B. *J. Org. Chem.* **2002**, *67*, 932–934.

(64) Johnson, C. R.; Adams, J. P.; Braun, M. P.; Senanayake, C. B. W.; Wovkulich, P. M.; Uskoković, M. R. *Tetrahedron Lett.* **1992**, *33*, 917–918.

(65) Yoshida, K.; Kawagoe, F.; Hayashi, K.; Horiuchi, S.; Imamoto, T.; Yanagisawa, A. *Org. Lett.* **2009**, *11*, 515–518.

(66) Donohoe, T. J.; Bower, J. F.; Basutto, J. A.; Fishlock, L. P.; Procopiou, P. A.; Callens, C. K. A. *Tetrahedron* **2009**, *65*, 8969–8980.

(67) The anhydride **III** can be trapped by a nucleophile such as simple amine like aniline. See: Kumar, A.; Srivastava, N.; Mital, A. *Ind. J. Chem., Sect. B* **1991**, *30*, 606–607.

(68) Nesmeyanov, A. N.; Ustynyuk, N. A.; Thoma, T.; Prostakov, N. S.; Soldatenkov, A. T.; Pleshakov, V. G.; Urga, K.; Ustynyuk, Yu. A.; Trifonova, O. I.; Oprunenko, Y. F. *J. Organomet. Chem.* **1982**, *231*, 5–24.

(69) Stauffer, K. J.; Williams, P. D.; Selnick, H. G.; Nantermet, P. G.; Newton, C. L.; Homnick, C. F.; Zrada, M. M.; Lewis, S. D.; Lucas, B. J.; Krueger, J. A.; Pietrak, B. L.; Lyle, E. A.; Singh, R.; Miller-Stein, C.; White, R. B.; Wong, B.; Wallace, A. A.; Sitko, G. R.; Cook, J. J.; Holahan, M. A.; Stranieri-Michener, M.; Leonard, Y. M.; Lynch, J. J. Jr.; McMasters, D. R.; Yan, Y. *J. Med. Chem.* **2005**, *48*, 2282–2293.

(70) Colandrea, V. J.; Naylor, E. M. *Tetrahedron Lett.* **2000**, *41*, 8053–8057.